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1 Introduction to HIV-1 and
Co-receptor Tropism
Auch die Pause gehört zum Rhythmus.
 Stefan Zweig
1.1 HIV and AIDS
1.1.1 History of HIV and AIDS
The Acquired Immunodeﬁciency Syndrome (AIDS) was ﬁrst described in 1981, with re-
ports of an accumulation of several rare conditions, unusual for the predominately young
group of patients [45, 92, 135, 40]. Similar cases were reported over the next months,
showing a distinct similarity, the drastic reduction of CD4-positive T-lymphocytes, an
important part of the immune system. It became clear, that the underlying cause for the
witnessed diseases was a deﬁciency of the immune system, making patients vulnerable to
opportunistic infections. Reports of hemophiliac patients with severe immune deﬁcien-
cies, prompted discussions about transmission through blood products [54]. The facts of
declining numbers of CD4-positive cells and the suspicion of transmissions through blood
put the focus on the human T-lymphotropic virus family (HTLV) [41], the only virus
known at that time to be able to infect CD4-lymphocytes [112]. The virus responsible
for the development of AIDS was successfully isolated by the group of Luc Montagnier
in 1983 [6], termed lymphadenopathy-associated virus (LAV) and again in 1984 by the
group of Robert Gallo [42], under the name of HTLV-III. The pathogen of the family of
lentiviruses, was later termed human immunodeﬁciency virus (HIV). The HI virus exists
in two variants, HIV-1 and HIV-2, both of which have probably emerged from the closely
related simian immunodeﬁciency virus (SIV) [132] found in monkeys. Through phyloge-
netic analysis the origin was dated to the late 19th or early 20th century in west-central
12
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Africa [166]. Since then AIDS has become a global epidemic, aﬀecting every country of
the world [54].
1.1.2 The Global AIDS Epidemic
Since the ﬁrst reported case of AIDS, the number of people living with HIV has steadily
increased (see Figure 1.1). In 1990 around 8 million total infections have been reported.
Twenty years later, this number has increased to over 33 million cases reported in 2008
[153]. From these, 22.5 million people are living in Sub-Saharan Africa, where the
combined overall prevalence, the percentage of people living with HIV, in adults (15-
49 years) is 5% (see Figure 1.2). In some regions in Southern Africa the prevalence is
as high as 25% [154]. In 2008 72% of all new HIV infections occurred in Sub-Saharan
Africa [103]. On the continent, HIV is the most common cause of death, and in some
regions has lead to a reduction of the average life-expectancy by almost 20 years [54].
Figure 1.1: Progression of the global epidemic. Source: United Nations Millennium
Development Goals Report 2010 [103]
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Despite these devastating facts, the newly published UNAIDS Report on the Global
AIDS Epidemic in 2010 [154] draws a more optimistic picture. The report highlights
an overall deceleration of the epidemic growth. Since the peak of epidemic spreading in
1997, when 3.2 million new infections were reported, this number has steadily decreased
to around 2.6 million in 2009, a reduction by 21% (see Figure 1.1). This trend is mostly
driven by the positive development in Sub-Saharan Africa, where the number of new
infections per year has dropped by almost 28% since 1997. The authors attribute the
successful reduction to HIV prevention eﬀorts, like safe-sex and prevention of mother-to-
child-transmission. A similar development is reported for the number of AIDS-related
deaths, shown in Figure 1.1. From the peak in 2004, when 2.1 million deaths were
reported, the number decreased steadily to an estimated 1.8 million in 2009. Again, the
trend is lead by a decrease in Sub-Saharan Africa which saw a reduction of 1.6 million
AIDS-related deaths in 2004 to around 1.3 million in 2009. This development is coupled
to the steadily decreasing number of new infections. It is also inﬂuenced by the improved
availability of antiretroviral therapy in low- and middle-income countries, where 42% of
people infected received therapy in 2008, compared to only 33% in 2007 [103]. With the
exception of Eastern Europe and Central Asia the epidemic appears to have stabilized.
Figure 1.2: Number of people newly infected with HIV. Estimated HIV/AIDS
prevalence among young adults (15-49) by country as of 2008 [161]. Based
on the UNAIDS Global Report 2008. Source: Wikipedia
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1.2 HIV Structure and Lifecycle
The human immunodeﬁciency virus consists of an envelope containing the viral core
which in turn contains several viral proteins and the viral genome [11]. A schematic
representation is given in Figure 1.3. The envelope, also known as coat, is of spherical
shape and about 120 nm in diameter. The coat is formed by a double layer of lipids,
extracted from the host cell membrane during the budding process by which new viruses
leave the cell. Inserted into the lipid membrane are a varying number of envelope (Env)
proteins required for virus cell entry [150]. The Env proteins are trimers of glycoproteins
120 (gp120) anchored to the lipid membrane by a trimer-bundle of alpha-helical gp41.
Each Env protein is about 10 nm in diameter [54]. At the interior side of the virus
envelope, matrix-proteins p17 are attached. The viral core structure, also referred to
as capsid, is contained in the envelope and has cone-like shape. Its outer structure
is formed by about 2000 copies of the matrix-protein p24. The capsid contains two
complete copies of the virus genome as RNA bound to the nucleocapsid protein p7, as
well as the viral enzymes reverse transcriptase, integrase and protease, required for the
replication process.
The primary target of HIV are T-cells, but other cells like macrophages or monocytes
can also be used as hosts for viral replication [16]. The life cycle of HIV goes from cell-
entry and uncoating, over reverse transcription and integration of the viral genome into
the host cell genome, to the assembly and maturation of new HIV virions. The complete
cycle is shown schematically in Figure 1.4.
The entry of HIV into host cells is mediated by interaction of viral coat-protein gp120
and cell the T-cell surface receptor CD4. In addition to CD4, host-cell chemokine re-
ceptors are required to establish the fusion of HIV with the host cell membrane and
complete cell entry. The entry process is central to this work and will be described in
detail in Section 1.4. After completing membrane fusion the viral capsid is released into
the cytoplasm, a process termed uncoating. The reverse transcriptase then detaches the
viral RNA from the p7 nucleoprotein and starts with the transcription into viral DNA.
This is done by synthesizing the cDNA strand complementary to the single stranded
viral RNA, which is, in parallel, being degraded by the reverse transcriptase. Subse-
quently, the complementary sense strand to the antisense cDNA strand is created. The
complete viral DNA molecules are then transported to the host cell nucleus where they
are integrated into the host genome by the HIV integrase. The transcription of the inte-
grated proviral DNA to mRNA is the next step towards the development of new virions.
The mRNA is cleaved into fragments coding for small regulatory proteins Tat and Rev.
15
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Figure 1.3: Schematic morphology of the HIV. Source: National Institute of Allergy
and Infectious Diseases (NIAID) [102]
Tat leads to an increased expression of viral mRNA, while Rev regulates the expression
of virus Gag-precursor, Gag-pol-precursor, and Env-precursor polyproteins. The Env-
polyprotein is cleaved by the HIV protease into gp41 and gp120 and inserted into the host
cell membrane. The Gag-, Gag-pol-precursors proteins, viral RNA, and several cellular
proteins are transported to the cell membrane, associating with the inner cell membrane,
where they are enclosed in the newly forming virion, starting the budding process. After
budding, virions are still immature. During the following maturation process, the HIV
protease cleaves the virus-membrane associated Gag-, and Gag-pol precursor-proteins
into their functional structural units, which then begin to form the virus capsid. By
the same protease, Gag-pol polyproteins are cleaved into functional virus enzymes. The
mature virus is now infectious, closing the replication cycle.
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Figure 1.4: Schematic representation of the HIV lifecycle. Source: National In-
stitute of Allergy and Infectious Diseases (NIAID) [102]
1.3 Antiretroviral Therapy
Many of the diﬀerent stages of the HIV replication are targets for antiretroviral drugs,
aiming at breaking the replication cycle, and thus, enabling an eﬀective antiretroviral
therapy (ART). According to the German-Austrian Guidelines for ART in HIV-1 Infec-
tions, the goals of antiretroviral therapy today, is to suppress infection-based symptoms,
slow disease progression, reestablish cellular immunity and reduce the chronic immune-
activation by inhibiting the HIV-replication [27]. To ensure this, the eﬀectiveness of the
17
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drug regimen, the combination of antiretroviral drugs, has to be sustained as long as
possible. Resistance mutations of the virus have to be avoided. This can be achieved
by maintaining a steady drug intake. A good patient compliance, however, is more
likely when side-eﬀects, a common problem of HIV therapy are limited to a minimum.
Eﬀective substances, causing severe side-eﬀects are not suited for therapy, as they will
probably lead to poor patient compliance. The central parameters, governing the success
of antiretroviral therapy are the eﬃcacy of drugs, the absence of resistances, and good
patient compliance [130], ensuring a consequent drug intake. The ﬁrst HIV therapies
were mono-therapies, consisting of single drugs administered to patients. Their eﬀec-
tiveness were, however, often compromised by rapid development of drug resistances.
Studies performed in the mid-1990s showed improved eﬀectiveness and reduced emer-
gence of drugs resistance using combination-therapies consisting of more than one drug
[18, 48]. Today, this therapy, known as highly active antiretroviral therapy (HAART)
is the accepted standard, with drug regimen consisting on average of three diﬀerent an-
tiretroviral drugs of diﬀerent classes. Indicators for the initiation of HAART taken from
the German-Austrian Guidelines (2010) [27] are diﬀerent for patient with and without
HIV-associated symptoms. In the latter case, initiation of HAART is generally recom-
mended. In the case of asymptomatic patients, the CD4 cell count, deﬁned as the number
of CD4+ T-Lymphocyte cells per volume (CD4/µl), is used as decisive measure. A low
CD4 count is a severe immunological condition, thus it is recommended that HAART
should be started with CD4 counts of less than 350/µl. The immunological success of
HAART is often deﬁned as achieving an increase in CD4 cell count. Unfortunately, the
immunological response is hard to inﬂuence, varies between patients, and is a weak in-
dicator for therapy outcome. Thus, for monitoring the success of HAART, CD4 cells
counts are not very well suited, because as a central part of the immune system, many
factors, besides HIV, will aﬀect the number of CD4 cells. The viral load (VL), a virolog-
ical parameter deﬁned as the number of copies of viral RNA per volume (copies/mL), is
easier to measure and serves as a direct indicator for the response to therapy [54]. To
circumvent a probable decrease in CD4 cell counts, it is recommended to initiate HAART
at viral loads of more than 100.000 copies/mL. Virological success is achieved by pushing
the VL under detection limits of 50 copies/mL, whereas virologic failure is regarded as
failing to reach VL of <50 copies/mL six months after initiation of HAART, or a VL
of >5000 copies/mL. Although VL and CD4 cell counts are correlated, virologic failure
does not always imply immunological failure [95, 24]. In fact, it seems more important
to achieve a reduction of viral load compared to the baseline (VL at treatment start),
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than to achieve the absolute VL of <50 copies/mL [78, 25]. Several studies have shown
beneﬁts of earlier treatment starts, such as the reduction of clinical complications and
side-eﬀects or improved immune reactions. In addition, low levels of viremia have been
shown to signiﬁcantly reduce the infectiousness and rate of sexual viral transmission [4].
The rate of progression towards AIDS was described as being higher for later treatment
starts, in several studies [110, 144]. However, earlier treatment increases the risk for
long-term toxicity and for developing drug resistances. Based on current knowledge,
HAART should be regarded as a life-long, continuous therapy.
1.3.1 Antiretroviral Drugs
In clinical HIV treatment four classes of drugs are currently administered. Entry in-
hibitors prohibit the virus from entering the host cell or integrating itself into the host
DNA where it would be replicated. Cell fusion can be inhibited by targeting virus
envelope proteins gp120 or gp41, as well as host co-receptor CCR5. Shortly after vi-
ral entry, reverse transcriptase inhibitors prohibit the HIV reverse transcriptase from
translating the single-stranded HIV RNA into double-stranded DNA. Reverse transcrip-
tase inhibitors are divided into nucleosidic- and non-nucleosidic reverse transcriptase
inhibitors, so-called NRTIs and NNRTIs. While NNRTIs are simply small-molecule
antagonists inhibiting a reverse transcriptase active site, NRTIs are nucleoside-analogs
that, when integrated, terminate chain elongation during the reverse transcription of
viral RNA to DNA. Integration of viral RNA into host DNA can be prevented by a rela-
tively new drug class blocking the HIV integrase. Another class, the protease inhibitors
(PI), are acting at a later stage of the virus life cycle. The HIV protease is blocked
in a way that the newly synthesized HIV precursor-polyproteins Gag, Gag-pol, or Env
cannot be cleaved correctly, resulting in defective proteins. Table 1.1 gives an overview
over drugs currently administered in clinical practice.
During the last years there has been a substantial focus on the development of a new
drug class: entry inhibitors. When interfering with the cell entry process, one can target
virus proteins, like other drug classes, or develop drugs that bind to host-cell proteins.
In the latter case, the virus cannot impair the drug binding aﬃnity, making it harder
to develop resistance mutations. Targeting the entry of HIV into the host cell is not an
entirely new ﬁeld. In the early 1990s so called attachment inhibitors attempted to block
HIV-1 gp120 by recombinant soluble CD4 (rsCD4) molecules. These were, however, dis-
continued due to low eﬃcacy in phase I clinical trials [23]. The ﬁrst entry inhibitor to
be licensed was enfuvirtide in 2003, targeting virus envelope protein gp41. A so called
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Table 1.1: List of antiretroviral drug classes used in ART. Adapted form the HIV-
Buch 2010 [54]
Trade Name Abbr. Substance Company Class
Emtriva FTC Emtricitabine Gilead NRTI
Epivir 3TC Lamivudine GSK NRTI
Retrovir AZT Zidovudine GSK NRTI
Videx DDI Didanosine BMS NRTI
Viread TDF Tenofovir Gilead NRTI
Zerit D4T Stavudine BMS NRTI
Ziagen ABC Abacavir GSK NRTI
Sustiva (Stocring) EFV Efavirenz BMS/MSD NNRTI
Viramune NVP Nevirapine Boehringer NNRTI
Intelence ETV Etravirine Tibotec NNRTI
Rescriptor DLV Delavirdine Pﬁzer NNRTI
Aptivus TPV Tipranavir* Boehringer PI
Crixivan IDV Indinavir* MSD PI
Invirase SQV Saquinavir* Roche PI
Kaletra LPV Lopinavir/Ritonavir Abbott PI
Norvir (as Booster)* RTV Ritonavir Abbott PI
Prezista DRV Darunavir* Tibotec PI
Reyataz ATV Atazanavir* BMS PI
Telzir (Lexivav) FPV Fosamprenavir* GSK PI
Viracept NFV Nelﬁnavir Roche/Pﬁzer PI
Celsentri (Selzentry) MVC Maraviroc Pﬁzer EI
Fuzeon T-20 Enfuvirtide Roche EI
Isentress RAL Raltegravir MSD II
Atripla ATP TDF+FTC+EFV Gilead+BMS+MSD Comb.
Combivir CBV AZT+3TC GSK Comb.
Kivexa (Epzicom) KVX 3TC+ABC GSK Comb.
Trizivir TZV AZT+3TC+ABC GSK Comb.
Truvada TVD TDF+FTC Gilead Comb.
post-attachment inhibitor, the monoclonal antibody ibalizumab binds to the host recep-
tor CD4, limiting the molecules ﬂexibility and hindering gp120 binding [13]. First results
have shown promising results, yielding a reduction in viral load of 1.5 log10 copies/mL
[74]. The discovery that a homozygous non-lethal deletion in the host cell chemokine
co-receptor CCR5 (CCR5∆32), results in immunity against HIV infections [59] while
the heterozygous deletion delays disease progression [79], spurred the development of
co-receptor antagonists, targeting CCR5. The HIV-1 cell entry mechanism, as well as
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targeting of host-cell co-receptors is central to the understanding of this work and will
be discussed in detail in Section 1.4.
1.3.2 Resistances and Testing
In untreated patients around 109 new virus particles are generated every day [109]. This
very high turnover rate of the HI virus, in combination with an error-prone replication
process  the reverse transcriptase generates around one mutation in 104 to 105 bases
per cycle  leads to a fast development of drug resistant viruses. This process can
best be suppressed by maintaining a constantly low level of viremia, minimizing the
amount of newly generated virus variants, and by administering at least two diﬀerent
drug classes, targeting diﬀerent steps of the virus replication cycle. Both aspects are
covered by current HAART, and patients today are less likely to develop virologic failure
due to resistance mutations than in the pre-HAART days [85, 77]. Still, regular tests for
drug resistance-related mutations are vital for ensuring eﬀective treatment and to adapt
the drug regimen accordingly. The German-Austrian therapy guidelines recommend
resistance testing prior to treatment start in therapy-naïve patients, and generally after
therapy failure in all patients [27], in order to determine the eﬀectiveness of future
treatments.
1.4 HIV-1 Cell Entry and Co-receptor Tropism
1.4.1 Entry mechanism
The entry of new host cells by the HIV virus is a multi-stage process, involving the
attachment, co-receptor binding and membrane fusion. The major viral component of
these processes is the viral spike, a trimeric complex of HIV envelope glycoproteins
(gp) gp41 and gp120. During HIV replication the glycoprotein gp160 is expressed as
polyprotein and subsequently cleaved into gp41 and gp120 by the HIV protease. The
viral spike consists of a multi-helix bundle structure of gp41 which is non-covalently
linked to the trimer of gp120.
The entry process begins by binding of the gp120 bridging sheet to the host-cell CD4-
receptor. This event triggers the detachment of the variable loop 3 (V3) of gp120 which
is now free to associate with a nearby host cell chemokine co-receptor, further stabilizing
the attachment of the virus to the host cell (see Figure 1.5). Next, the previously
inaccessible gp41 is inserted into the host cell membrane and mediates fusion of the
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Figure 1.5: HIV envelope spike structure. Structure of the trimeric envelope spike.
Trimeric gp120 (green) is bound to cell receptors CD4 (blue). The V3 loop
(red) is detached and extends into the solvent after CD4 binding. Based on
PDB structures 2QAD [56], electron microscopy data (white shade) from Liu
et al. [83]
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lipid membrane of the virus and host cell [60]. Glycoprotein gp120 can interact with
diﬀerent classes of chemokine co-receptors, although most commonly either Chemokine
Co-receptors CCR5 or CXCR4 are used. Both belong to the family of G-Protein Coupled
Receptors (GPCR), the largest and most diverse group of receptors involved in signaling
in eukaryotes [89]. The human genome holds over 1000 GPCRs, including receptors
for odors, hormones, nucleotides, pheromones and many more. GPCRs are involved in
many biological processes, making them major targets for medical drugs. Over 26%
of drugs approved by the American Food and Drug Association (FDA) are targeting
Rhodopsin-like GPCRs [107].
Figure 1.6: Schematic representation of a G-Protein Coupled Receptor
(GPCR). The seven membrane-spanning helices (I-VII) are connected by
three extracellular loops (ECL 1-3), three intracellular loops (ICL 1-3) while
the ﬁrst (I) and last (VII) transmembrane helix have an N-terminal and
C-terminal domain, respectively.
The structure of these integral membrane proteins consists of seven membrane-spanning,
or transmembrane (7TM) α-helices linked by loops of varying length and structure (see
Figure 1.6). Accoding to their location, these loops are referred to as extracellular or
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intracellular loops (three ECLs and three ICLs, respectively). In chemokine co-receptors,
cysteines forming stabilizing disulﬁde bridges are common features of the extracellular
loops. The N-terminal tail of both CCR5 and CXCR4 extend into the cell exterior, while
the C-terminus reaches into the cytosol. Certain residues on both termini are often sub-
ject to post-translational modiﬁcations like serine and threonine to phosphorylation or
tyrosine to sulfation. A homology model of the CCR5 co-receptor embedded in a lipid
membrane is shown seen in Figure 1.7. CCR5 is most commonly expressed on T-Cells,
macrophages, dendritic cells and microglia, the primary ligands are pro-inﬂammatory
cytokines MIP-1α, MIP-1β, and RANTES, all of which have been found to act as com-
petitive inhibitors against HIV infection [86].
Figure 1.7: Model of CCR5 in lipid bilayer. The picture shows a homology model of
the human CCR5 co-receptor (red transmembrane helices and green loops)
embedded into a lipid bilayer slab (mint green).
The type of co-receptor used by the virus to induce cell fusion is strongly dependent
of the V3 loop of gp120. This loop of, on average, 35 aminoacids is very variable in pri-
mary sequence, mutations including substitutions, deletions, and insertions (see Figures
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1.8 and 1.9). The Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/)
currently contains around 36.000 unique V3 sequences. Next generation sequencing ex-
periments of HIV positive patients have revealed quasispecies diversity of hundreds of
unique sequences in some patients [151, 121]. The extent, however, to which minor
variants are caused by sequencing errors is still unclear.
Figure 1.8: Length distribution of the variable loop 3 (V3) of HIV gp120. Se-
quence lengths of the two classes (R5 and X4) show a clear diﬀerence, with
the X4 sequences having a tendency towards shorter (33) loop sizes. Se-
quences with known co-receptor tropism were taken from the Los Alamos
HIV Sequence Database (http://www.hiv.lanl.gov/).
1.4.2 Structural Data
In recent years, various groups have successfully determined the structure of proteins
involved in the HIV cell entry mechanism. In 1996 Wu et al. [168] solved the struc-
ture of T-Cell CD4, including various mutants unable to bind gp120. Two years later,
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Figure 1.9: Weblogos of clonal V3 sequences. Weblogos [21] showing the frequency
of aminoacids for the diﬀerent sequence positions of the V3 loop. Weblogos
were generated for both the R5 (top) and X4 (bottom) tropic sequences.
Both logos show the strong heterogeneity of the V3 loop. Sequences with
known tropism were acquired from the Los Alamos HIV Sequence Database.
CD4 was crystallized by Kwong et al. [75], bound to gp120 and a neutralizing antibody.
This study shed light on the interaction of gp120 and CD4, however the ﬂexible V3
region was not captured and structural features remained unknown until 2005, when the
group of Huang [57] successfully solved the structure of gp120 in complex with CD4 and
an antibody. Earlier, several groups had already experimented with V3-like peptides
[159, 152, 131, 119]. In 2008, gp120 was already well known and studied as a monomer,
when Liu et al. [83] solved the biological trimeric gp120 of the viral spike bound to
CD4, by means of cryo-electron tomography. The published electron density map covers
the complete HIV viral spike, including gp41. Just recently, Liu et al. [84] have solved
the monomeric form of the C-terminal ectodomain of gp41, responsible for interaction
with gp120. These advances are very promising and suggest the complete structural
determination of the viral spike within the next few years. Unfortunately, the remaining
proteins involved in the fusion process, host chemokine co-receptors CCR5 and CXCR4,
are not well described structurally, as crystallization of integral membrane proteins like
GPCRs is challenging [170]. A major challenge is ﬁnding a suitable type of lipid to form
a host micelle for the protein. Then, proteins have to be puriﬁed without losing lipid
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Figure 1.10: Structure of the V3 loop. The V3 loop is shown as blue ribbon and ex-
tends from one of the gp120 envelope proteins of the gp120 trimeric structure
which is shown in the box in the lower left corner. V3 loop structure taken
from PDB structure 2QAD [56].
association. Additionally, exposed and ﬂexible loops, often found in GPCRs, are subject
to protease degradation. Until recently, the only structural entry of human chemokine
co-receptors CCR5 and CXCR4 were short fragments of the N-terminal extracellular
domain. In 2007 Huang et al. [56] presented the crystal structure of gp120 bound to
CD4 and a tyrosine-sulfated antibody targeting the V3 loop. They found that one of
the sulfated tyrosines seems to mimic the binding of the N-terminal co-receptor domain.
To test their hypothesis, a short N-terminal peptide of CCR5 including residues 5-12
was solved by Nuclear Magnetic Resonance (NMR). Docking of the peptide to the crys-
tallized V3 loop yielded the ﬁrst experimentally determined structural model for the
interaction of gp120 with a co-receptor. The structure of the N-terminus of CXCR4,
in form a peptide bound to its natural ligand, the chemokine SDF-1, has been solved
in 2008 [157]. From that structure it has been hypothesized that N-terminal tyrosines
are sulfated, due to their interaction with positively charged clefts on SDF-1. How-
ever, a real breakthrough, which will further clarify the binding mode of V3 to host cell
co-receptors was published just prior to this work. In late 2010, Wu et al. published
ﬁve independent crystal structures of CXCR4 with bound small molecules and a cyclic
peptide at high resolutions [167]. Structural data of the complete CCR5 co-receptor
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remains unavailable. However, template structures for homology modeling experiments
of CCR5 are available, like the GPCR structures of bovine rhodopsin [108] or human
β2 adrenergic receptor [116]. Especially the crystal structure of bovine rhodopsin has
been used as template for molecular modelling of the chemokine co-receptors CCR5 and
CXCR4 [155, 101, 138].
1.4.3 Small-Molecule CCR5 Antagonists
Several companies have ventured to develop antagonists targeted against CCR5. How-
ever, most of the drugs that went to clinical trials have been discontinued, due to limited
eﬃcacy of adverse eﬀects. The ﬁrst small-molecule antagonist TAK-779, developed by
Takeda Pharmaceutical was dropped due to poor oral availability [70]. A structural suc-
cessor (TAK-652), now developed as Cenicriviroc by Tobira Therapeutics, is currently in
clinical trials showing good viral potency and encouraging eﬃcacy [69]. Aplaviroc was
developed by GlaxoSmithKline until 2005, when cases of drug-related liver toxicity [104]
and limited eﬃcacy [22] lead to discontinuation of development. Until 2010 two small-
molecule co-receptor antagonists, maraviroc and vicriviroc, showed promising results in
various clinical trials and will be discussed in the following.
Maraviroc
The most successful CCR5 small molecule antagonist, maraviroc (MVC) [30] most likely
binds to a hydrophobic cavity within the transmembrane domain of the CCR5 co-receptor
[70], blocking interaction of HIV gp120. The hypothesized binding mode is shown in Fig-
ure 1.11. In 2007, maraviroc has been approved by the FDA and was recommended for
treatment experienced patients. The drug was discovered through cell-based screening
assays and was found to be an eﬀective CCR5 antagonist, not aﬀecting CCR5 expression
levels or interfering with intracellular signaling. In vitro studies showed a good inhibitory
activity of maraviroc against 43 diﬀerent primary virus isolates as well as 200 clinically
derived HIV-1 envelope-recombinant pseudoviruses. Additionally, maraviroc proved ef-
fective against primary isolates with known resistances against NRTIs, NNRTIs and PIs
[90].
Prior to the approving of maraviroc by the FDA, two identical, parallel, double-blind,
placebo-controlled phase III studies were carried out to determine the eﬃcacy of mar-
aviroc in treatment experienced adult patients with CCR5 HIV-1 infections [46]. The
so-called MOTIVATE (Maraviroc plus Optimized Therapy In Viremic Antiretroviral
Treatment Experienced patients) studies 1 and 2 assessed the eﬃcacy and safety of
28
1.4. HIV-1 Cell Entry and Co-receptor Tropism
1
Figure 1.11: Skeletal formula and putative binding mode of maraviroc to
CCR5. Illustration taken from Kondru et al. [70]
maraviroc over a time of 48 weeks, followed by an extension to period to 96 weeks. MO-
TIVATE 1 was carried out in the US and Canada, while MOTIVATE 2 took place in
Europe, Australia and the US. Patients eligible to enroll had to be infected with R5 virus
only, and have a viral load of more than 5000 copies/mL. In total, 601 and 474 patients
were included into MOTIVATE 1 and 2, respectively. The study populations were ran-
domized and split in to three arms receiving placebo or maraviroc once or twice daily.
In addition, each patient received an optimized background therapy (OBT) adjusted to
patient-speciﬁc resistances, consisting of three to six agents of NRTI, NNRTI, PI, and
fusion inhibitors. The eﬃcacy of maraviroc was analyzed at the primary end-point at
week 48. In both studies MOTIVATE 1 and 2, patients receiving maraviroc plus OBT
showed a signiﬁcantly stronger reduction of viral load compared to patients receiving
placebo plus OBT. The eﬃcacy of the twice-daily arm was also signiﬁcantly higher than
the once-daily arm. The pooled results of both studies showed a mean change of viral
load of -0.79, -1.68, and -1.84 log10 copies/mL for the placebo, once-, and twice-daily
arms. The frequency of adverse eﬀects was described as being equal between the diﬀerent
arms.
In the MOTIVATE studies maraviroc was administered to treatment experienced pa-
tients, however the highest frequency of R5 viruses, target of maraviroc is witnessed in
treatment naïve patients [96]. The MERIT (Maraviroc versus Efavirenz in Treatment-
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Naive Patients) phase III study compared the eﬃcacy and safety of maraviroc to efavirenz
in treatment-naïve patients [19]. The study was started in 2004 and aimed at showing
maraviroc to be non-inferior to the NNRTI efavirenz in combination with the regular
drug regimen at that time (NRTIs zidovudine and lamivudine). The study setup was
similar to that of the MOTIVATE studies and carried out in Australia, Europe, South
Africa, North and South America. The three study arms consisted of patients receiv-
ing maraviroc once-daily, twice-daily or efavirenz once-daily, each in combination with
lamivudine and zidovudine. The maraviroc twice-daily arm established non-inferiority
to efavirenz after 48 weeks with 70.6% of patients (maraviroc, twice-daily) reaching a
viral load of <400 copies/mL, while 73.1% of patients receiving efavirenz reached that
goal. A reanalysis of the results was performed after it had become clear that the as-
say for determining exclusive R5 virus in patients lacked desired sensitivity. A post hoc
re-screening of patients, using an enhanced version of the same assay, revealed X4-using
virus in an additional around 15% (106 of 721) patients. A reanalysis, excluding these
patients, showed an improvement of therapy outcome on the maraviroc twice-daily arm.
A viral load of <400 copies/mL was achieved by 73.3% of patients receiving maraviroc,
compared to 72.3% of efavirenz-receiving patients.
Vicriviroc
Vicriviroc (VVC) is a small-molecule CCR5 antagonist initially developed by Schering-
Plough [73]. Both skeletal formula and binding mode are similar to maraviroc (compare
Figure 1.12) [70]. The drug has been shown to have a good oral bio-availability and long
half-life and thus can be administered once daily [62].
The AIDS Clinical Trials Group (ACTG) 5211 phase II study was carried out to
determine the eﬃcacy of vicriviroc in treatment-experienced patients over a period of
initially 48 weeks [47] and a follow up until week 96 [162]. The study setup was similar
to the MOTIVATE 1 and 2 studies: double-blinded, placebo-controlled, and random-
ized. Patients were then randomized to four groups receiving 5, 10, 15 mg of vicriviroc
once daily or placebo, respectively, with a background regimen containing the protease
inhibitor ritonavir. At 24 weeks the mean change of baseline viral load was -0.29 log10
copies/mL for the placebo arm, and -1.51, -1.86, and -1.68 log10 copies/mL for the 5, 10,
and 15 mg VVC arms, respectively. The 5 mg VVC study arm was discontinued after
48 weeks due to suboptimal treatment results.
In the recent double-blinded, placebo-controlled, phase III VICTOR-E3 and E4 studies
[44] vicriviroc surprisingly failed to establish superior eﬃcacy over a placebo control
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Figure 1.12: Skeletal formula and putative binding mode of vicriviroc to CCR5.
Illustration taken from Kondru et al. [70]
group. The VICTOR-E3 study was carried out in South America, the VICTOR-E4 study
took place in Australia, Europe, South Africa and the US. Study setup was identical,
including treatment experienced patients with exclusive R5-virus. The two arms of
both studies consisted of regimen of 30 mg VVC or placebo, both with OBT. Pooled
results show that after 48 weeks 64% of VVC-receiving patients achieved viral loads
of <50 copies/mL, compared to 62% of patients in the placebo arm. 72% of VVC-
patients achieved viral loads of <400 copies/mL, the same was achieved by 71% of
placebo patients. The authors attribute this disappointing result to the success of the
OBT. Of all those patients receiving a background regimen with less than three drugs,
70% patients of the VVC arm achieved VL < 50 copies/mL, compared to only 55% of
placebo-receiving patients. Using the same measure, no signiﬁcant diﬀerence between
the arms can be seen for patients receiving more than three or more drugs in their
background regimen. Overall, 67% of patients received a strong background regimen
(>3 drugs), compared to only 37% in the MOTIVATE studies. In summary, VVC was
shown to be safe and well-tolerable but failed to meet eﬃcacy end-points, which lead
to the termination of all ongoing vicriviroc studies. Merck, developing vicriviroc after
merging with Schering-Plough, has decided to not further pursue regulatory approval.
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Eﬀect of X4 Virus Presence on Therapy Outcome
The results from the MERIT study highlighted the strong inﬂuence of X4 viruses on
therapy outcome for co-receptor antagonists. In the initial analysis of the MERIT study,
around 15% of patients included had signiﬁcant levels of X4 virus, reducing the eﬃcacy
of maraviroc for the study group. Detection of the X4 virus in these patients by a
ﬁrst generation phenotypic assay failed, and was only achieved with an enhanced, more
sensitive version, during reanalysis. The post hoc removal of misclassiﬁed patients yielded
better results, and maraviroc established non-inferiority to efavirenz under the condition
of treating R5 virus patients only. The ineﬀectiveness of maraviroc on patients with X4
virus has been described in an earlier phase II placebo-controlled study where the eﬃcacy
of maraviroc on treatment experienced patients with X4 virus and a viral load of >5000
copies/mL was examined [93]. This study showed no signiﬁcant diﬀerence changes in viral
load between the maraviroc and placebo group. Taken together these results underline
the importance of a sensitive and reliable detection of X4 viruses, prior to administrating
co-receptor antagonists, like maraviroc to treatment experienced patients.
1.4.4 Phenotypic Testing of Co-receptor Tropism
Phenotypic test have long been the standard way of determining co-receptor tropism.
Most cell-based assays, like Phenoscript R©(VIRalliance) [120], PhenX-R R©(inPheno) [49],
Troﬁle R©[160] and the Enhanced Sensitivity Troﬁle R©Assay (ESTA) [149] (both Mono-
gram Biosciences), rely on expressing patient-derived env genes in combination with
replication-defective HIV virions. Over the last few years, the Troﬁle assay has es-
tablished itself as the gold-standard in phenotypic HIV tropism testing and has been
used for the characterization and clinical development of HIV-1 co-receptor antago-
nists [96, 47, 46, 44]. In the Troﬁle assay virus env genes are extracted from patient
plasma, ampliﬁed by Reverse transcription-PCR and inserted into expression vectors.
A replication-defective vector, carrying HIV genes of the NL4-3 strain of HIV-1, where
the env gene was substituted for a luciferase cassette, is co-transfected with the patient-
derived env library into human embryonic kidney 293 (HEK293) cells. Viral stocks of
pseudo-virions are then harvested and used to infect cells expressing CD4 and either
CCR5 or CXCR4. The successful infection of the respective cell lines is measured by
luciferase activity and thus allows determination of co-receptor tropism. Possible out-
comes are the detection of R5 or X4 viruses, that exclusively infect cells via CCR5 or via
CXCR4, respectively, and of dual-tropic or virus mixtures (DM). The standard Troﬁle
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assay has recently been improved and was shown to be eﬀective in detecting very small
concentrations of X4 viruses. Reanalysis of patients enrolled in the MERIT study has
demonstrated the improved performance and clinical value of the enhanced Troﬁle. How-
ever, phenotypic tests have important drawbacks: e.g. Troﬁle is expensive (1800 USD
in 2008 [90]), has long turnaround times of about 16 days [118], is limited to specialized
laboratories [54], and fails to produce results for viral loads of <1000 copies/mL (15%
of cases [114]). Currently, German health insurance does not cover costs for phenotypic
tropism testing [54]. Diﬀerences in sensitivity and outcome of various phenotypic tropism
test have been reported repeatedly [148, 158].
1.4.5 Genotypic Testing of Co-receptor Tropism
The importance of accurate methods for determining the HIV co-receptor tropism has
already been discussed. Phenotypic, cell-based assays, like Troﬁle have been applied in
various clinical studies (see Section 1.4.4) and, with the recently improved sensitivity, are
considered a useful indicator for the eﬀectiveness of co-receptor antagonists. However,
the potential progression of co-receptor antagonists towards ﬁrst-line therapy, there is a
growing need for cheaper and faster methods. Early on, it has been noted, that the V3
loop of gp120 is the main determinant of co-receptor tropism [61]. Simple rules like the
11/25 rule are capable of predicting tropism by evaluating the sidechain charge of posi-
tions 11 and 25 within the V3 loop sequence with fair success [39, 133]. In the past years
diﬀerent groups have devised a variety of mostly machine-learning-based methods to pre-
dict co-receptor tropism, considerably improving prediction accuracy [117, 111, 65, 136].
These methods rely on a set of V3 loop sequences with known associated co-receptor
tropism, from which tropism-speciﬁc sequence features can be extracted. The generated
models can then be used to predict the tropism of new V3-loop sequences, by evalu-
ating the derived features. Diﬀerent machine learning methods have been applied, like
artiﬁcial neural networks [117], support vector machines [111, 136], or position-speciﬁc
scoring matrices [65]. While most of these methods rely exclusively on V3 loop sequence
information, it has been shown that additional information, like clinical parameters (CD4
cell counts, viral load) [136] or V3 loop structure models [126] can further improve pre-
diction accuracy. Several groups have made their methods publicly available by oﬀering
web-services (see Table 1.2). While all of the services are free-of-charge and at least in
principle able to generate predictions within seconds, there are severe diﬀerences in terms
of usability. Here, wetcat serves as a negative example, requiring an initial alignment to
be generated manually (accessed December 2010).
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Table 1.2: Publicly available genotypic co-receptor tropism prediction methods
Name URL Method
Web-PSSM http://indra.mullins.microbiol.washington.edu/webpssm/ PSSM
geno2pheno http://coreceptor.bioinf.mpi-inf.mpg.de/ SVM
wetcat http://genomiac2.ucsd.edu:8080/wetcat/v3.html SVM
1.5 Research Motivation
In the past years there have been a number of publications pointing out that the per-
formance of current genotypic prediction methods, compared to the results of state-of-
the-art phenotypic tests was still inadequate. With the development and introduction of
co-receptor antagonists like maraviroc and vicriviroc, there was, and still is, a need for
reliable determination of co-receptor tropism. The possible introduction of maraviroc or
other entry inhibitors as ﬁrst-line drugs, also calls for cheaper, faster, and broadly avail-
able methods. The motivation for this work was to identify ways to improve genotypic
co-receptor tropism prediction. This can be achieved for one, by developing a method
with an improved prediction accuracy on data of the current clinical practice and will
be elucidated in Chapter 2, or by application to more complex and reliable data, as will
be the topic of Chapter 3.
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2 Prediction of HIV-1 Co-receptor
Tropism from Genotype
No matter how good you are, you're going to lose one-third of
your games. No matter how bad you are you're going to win
one-third of your games. It's the other third that makes the
diﬀerence.
 Tommy Lasorda
2.1 Introduction
Computational models for predicting drug resistances from virus protein sequences have
already become a standard procedure in HIV antiretroviral therapy and are explicitly
included in the current German-Austrian Guidelines for ART in HIV-1 infections [27].
When the FDA approved maraviroc in 2007, computational methods for predicting pa-
tients co-receptor tropism were already available [117, 111, 65, 136, 126], but various
studies found rather unsatisfying discordance between predictions by these genotypic
methods and results obtained by state-of-the-art phenotypic assays [87, 139, 88]. Most
of these applied machine-learning methods generate models able to distinguish R5 from
X4 V3 loop sequences. Motivated by promising results of previous machine-learning-
based prediction methods, the aim of this work, described in this chapter, was to explore
ways of improving co-receptor tropism predictions. In the following, a new co-receptor
tropism prediction model, relying on two diﬀerent descriptions of V3 loop sequences will
be presented. The model was trained using suitable sequences selected from the vast
collection of the Los Alamos HIV Sequence Database and tested on an independent set
of clinical sequences gathered in various laboratories in Germany, comparing it to current
state-of-the-art methods.
35
2.1. Introduction
2
2.1.1 Machine Learning in Biology
Machine learning, very generally, describes a ﬁeld of artiﬁcial intelligence dealing with
algorithms for pattern recognition, classiﬁcation and prediction from models which were
derived using existing data [146]. Machine learning algorithms are used to extract char-
acteristic features from concrete example data to generate models which can in turn be
applied to classify, recognize, or interpolate new data. The data consists of a set of obser-
vations (data points), where each observation contains a set features, or variables. In a
biological context, observations consisting of features could be protein or DNA sequences
consisting of aminoacids or nucleotides. The features depend on the description of the
observation. So-called descriptors are used to created diﬀerent sets of features. A pro-
tein, for instance, could be described as a sequence of aminoacids, secondary structure
elements, or simply by properties such as volume, charge or mass. Some descriptors are
more powerful than others, because they capture more details, or more important de-
tails. The ﬁeld of machine learning is divided into supervised and unsupervised learning.
In unsupervised learning, observations are grouped, or clustered, based on similarity. A
prominent example is the discovery of the archae by Carl Woese and George Fox in 1977
[163]. Using the sequences of the 16s ribosomal RNA from a variety of microorganisms,
Woese and his colleague constructed a similarity matix, measuring the pairwise distances
between all sequences. Surprisingly, next to clusters representing the known groups of
prokaryotes and eukaryotes, a third cluster became evident  the archae. Unsupervised
learning methods like clustering are popular in phylogenetic or microarray analyses. In
supervised learning observations are linked to classes. Machine learning methods will try
to generate classiﬁers which relate the classes associated with the observations, based on
rules generated from characteristic features found. The trained model, or classiﬁer, can
then be used to classify new observations. Popular classiﬁcation problems in biology are
secondary structure prediction from protein sequences or prediction of drug resistance
from patient data.
2.1.2 Random Forests
Ensemble classiﬁers are sets of classiﬁers, applied to the same classiﬁcation problem. The
ﬁnal step is the joint prediction of all single classiﬁers through fusion. The variety of
fusion methods is vast: majority vote [15], minimum or maximum prediction, multiplica-
tion, or even the use of another machine-learning model [165]. The single classiﬁers can
also result from diﬀerent machine learning approaches, e.g. artiﬁcial neural networks,
36
2.1. Introduction
2
support vector machines or k-nearest neighbors algorithms. Optimally, these methods
use diﬀerent descriptors, trying to separate the observations in diﬀerent feature spaces
[53]. Nanni and Lumini applied classiﬁer ensembles for HIV-1 protease cleavage predic-
tion [100]. They used linear support vector machines trained on diﬀerent feature subsets
and fused them by summation. It has been shown in theoretical and empirical studies
that combining classiﬁers trained using diﬀerent descriptors can improve class prediction
accuracy compared to a single classiﬁer with combined feature space [169, 123, 32]. On
the other hand, it may be unwise to combine too many classiﬁers as this can lead to
suboptimal prediction performance [71, 123]. The descriptor selection can be crucial for
the prediction performance [106]. Descriptor selection approaches, such as genetic algo-
rithms or clustering, have been proposed to ﬁnd optimal descriptor sets [99, 134, 72, 68].
The random forest algorithm was created by Leo Breiman in 2001 [10]. Random forests
are ensemble classiﬁers consisting of decision trees. Each tree is unique and has been
constructed, using a randomly selected subset of features found in randomly sampled
subsets of the training data. When classifying new observations of unknown class, the
ﬁnal prediction is based on the majority vote of the single decision trees. Random
forests have been shown to be very accurate and fast [10]. Notably, predictive power
has been shown to converge with a growing number of generated trees, eliminating one
possible source of overﬁtting [10]. In contrast to other machine learning algorithms,
like neural networks or support vector machines, random forest estimates error rate and
feature importance during construction. Decision trees and their construction comprises
a number of concepts that are explained in the following.
Decision Trees
Schematically, a decision tree is a set of subsequent branching operations, based on the
evaluation of predeﬁned tests. A decision tree consist of three key elements (see Figure
2.1.2):
1. Nodes (Boxes): Test
2. Leaves (Circles): Decision
3. Branches (Lines): Consequence of test. Connecting nodes with leaves or nodes.
Figure 2.1.2 shows a binary decision tree. In a binary decision tree each inner node is
only connected via three branches, every test having exactly two outcomes. The decision
process always starts at the topmost node (here, Test I). When the ﬁrst test evaluates to
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false, the corresponding branch leads to leaf with a negative decision. The overall result
of the decision tree is 'No'. If the ﬁrst test evaluates to true, the corresponding branch
leads to a second node, representing an additional test. The result of this second test
will lead to a ﬁnal decision, as both resulting branches lead to a leaf.
Figure 2.1: Example of a binary decision tree.
Binary decision trees are simple examples of trees. More complex trees can accom-
modate more than two test results. The decision tree depth describes the longest path,
in units of branches, through the tree until reaching a decision. A practical example
is given in the work of Beerenwinkel et al. [7] where decisions on drug resistance or
susceptibility are made, based on the evaluation of the type aminoacids at diﬀerent pro-
tein sequence positions. Figure 2.1.2 shows two trees taken from that work. The trees
were grown to predict resistance or susceptibility for delavirdine (h) and efavirenz (i),
two drugs targeting the reverse transcriptase of HIV-1. In this example the components
nodes, branches and leafs represent:
1. Nodes: Evaluation of aminoacid at given sequence position
2. Leaf: Decision on susceptibility (green) or resistance (red)
3. Branch: Consequence of aminoacid found a given position
To predict the drug susceptibility or resistance of delavirdine for a new reverse tran-
scriptase sequence, one again starts at the topmost vertex of the tree (h) and evaluates
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which aminoacid is present at position 103. Possible outcomes are decisions on sus-
ceptibility (L) or resistance (N,Q, or T), and a further test of the aminoacid at either
positions 122 (E), 181 (K), 179 (R), or 211 (S). In that way, one proceeds down the tree
until either a decision (leaf) is reached, or a test fails to produce a results. The latter is
the case if the aminoacid found a given position during testing is not associated with a
branch, and thus, no prediction can be made.
Figure 2.2: Decision tree predicting drug resistance against RT inhibitors. De-
cision tree taken from Beerenwinkel et al [7]. Here a decision on drug resis-
tance is made, based on the aminoacids present at deﬁned sequence positions.
The trees predicts the resistance or susceptibility to delavirdine (left, h) and
efavirenz (right, i).
Bootstrapping and Bootstrap Aggregating (Bagging)
In statistics, bootstrapping is a resampling method. It is used to approximate estima-
tors, such as average or variance, of an existing dataset by determining the distribution
of the estimator over a number of datasets resampled from the original. For generat-
ing resampled sets a random sampling with replacement is used. In machine learning,
bootstrap aggregation (short: bagging), is closely related to bootstrapping and is used
to improve prediction or regression ensemble classiﬁer models. An ensemble of classiﬁers
is created by aggregating multiple bootstrapped samples (in-bag data) of the training
data and constructing one decision tree from each sample. During bagging the in-bag
data consists of 63% of the training data [9]. For each sample, the data not used for
training is referred to as out-of-bag (OOB) data and used for evaluation of performance,
error, etc. Results of classiﬁcation, regression or error estimation are averaged over the
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complete ensemble. By bagging, models become more stable in terms of prediction and
overﬁtting is usually avoided.
Approximation Using OOB Data
The random forest algorithm performs an internal crossvalidation during training. The
goal of crossvalidation is to estimate the performance of the model on a data set that
is independent to that used for model training. For that purpose, the OOB data of
every tree is used to calculate model estimators like error-rate, prediction performance,
or variable (feature) importance. The model performance for each observation n in the
training data is estimated by classifying n by each tree where it was out-of-bag, thus not
used for tree construction. The ﬁnal prediction for n is fraction of votes for one of the
classes. By the same manner, the error rate of the forest can be estimated. The error
estimate is then given by:
Eforest =
1
N
N∑
n=1
Etree(p(n), yn)
with
Etree(p, y) =
0, if p = y1, if p 6= y
where N is the number of observations, p(n) is the class predicted for observation n
by majority vote of all models where n was OOB, and yn is the true class of n.
Importance Analysis
Machine learning methods are often referred to as 'black boxes'. After model training
it is complicated to understand what the models have learned. Random forests allow
an in-depth view into the learned classiﬁcation mechanism by examining single decision
trees. A faster and more elegant approach is, however, directly implemented in the
random forest algorithm: importance analysis. The importance of every variable for the
successful classiﬁcation is estimated by comparing the number of correct classiﬁcations of
OOB data of each tree with those of a set of permuted OOB data. For every tree that is
constructed, each variable of the OOB data is permuted and classiﬁed by the respective
tree. The diﬀerence between the classiﬁcation error of the original and permuted OOB
data is recorded and averaged over all trees and normalized by the standard deviation
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of the diﬀerences. The importance of each variable is the estimated percent decrease in
prediction accuracy [82].
Growing Decision Trees
Each decision tree as single classiﬁer for the random forest is constructed as follows:
1. From N training data, a bootstrap sample of size N is generated.
2. If the N training data consists of N · M variables, choose a number m  M ,
representing the number of variable used at each tree node.
3. At each tree node, randomly choose m variables to base the test on.
4. Choose the best test to split the training data into the respective classes.
5. Repeat 3 and 4 until tree is fully grown.
6. Evaluate estimators (error rate, predictive performance, variable importance) using
the OOB data.
Classifying New Data
Once a random forest has been trained, the model can be applied to new data for
classiﬁcation or regression, depending on the type of model. When classifying new data,
the resulting prediction for an observation is a pseudo probability of belonging to a class.
It is the arithmetic mean of the single tree decisions:
p = 1
N
N∑
i=1
pi
where N is the number of trees in the ensemble and pi is the decision of a single tree.
For this work, the random forest algorithm was chosen as the machine learning method
of choice.
2.1.3 Structural Descriptor: The Electrostatic Potential
The 11/25 and 11/24/25 rules, as well as the V3 charge rule imply the importance of
electrostatic interactions of V3 and the co-receptors CCR5 or CXCR4 for discriminating
between R5 and X4 viruses. In order to analyze whether there exists a diﬀerence in the
electrostatic potential of the co-receptors, homology models of both CCR5 and CXCR4
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were kindly built by Dr. Steﬀen Wolf from the Biophysics Group at the Ruhr University
in Bochum. The template selection and modeling process are described in detail in
the Materials and Methods Section (2.2). The electrostatic potential at the solvent-
accessible surface of the extracellular regions of co-receptors CCR5 and CXCR4 are
shown in Figure 2.3. It can be seen that the electrostatic potential at this region is quite
distinct between the models. While CCR5 (left) has a largely positive potential, shown
in blue, the potential of CXCR4 (right) is found to be more negative, shown in red. This
is accordance with the 11/25 and 11/24/25 rules, stating that X4 loops often have a
positively charged aminoacid at positions 11 or 25.
Figure 2.3: Electrostatic potential of the extracellular region of Chemokine
co-receptors CCR5 and CXCR4. The computed electrostatic potential
of the extracellular region of CCR5 (left) is largely positive as shown by
the blue surface. In comparison the extracellular electrostatic potential of
CXCR4 (right) is overall more negative. Unit of electrostatic potential in
kB · 300K/e. Details on the computation are given in Section 2.2
The rule-based approaches of 11/25 and 11/24/25 are, however, biased by the under-
lying sequence alignment. Prior to prediction of co-receptor usage, most methods are
aligning the target sequence to be predicted to a reference V3 loop sequence. In the case
of the 11/25 and 11/24/25 rules the HXB2-V3 loop sequence is used as reference. The
sequence numbering is relative to the reference and residues aligned to reference positions
11, 24, and 25 are thus dependent on the alignment procedure. The requirement of a
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positive charge at one of the alignment positions does not mean that a positive net charge
is required for the natural binding mode of an X4 virus to the CXCR4 co-receptor. For
instance, one could imagine a compensatory mutation at a diﬀerent sequence position,
neutralizing the net charge. This is in part covered by the charge rule, which considers
the sum of all charges within the V3 loop and discriminates X4 from R5 viruses by the
V3 net charge. However, while gaining information on possible compensatory charges at
positions not included in the 11/25 or 11/24/25 rules, information on the sequence posi-
tion of charges is lost. We hypothesize that it is more feasible to consider an aminoacid
within the spatial ensemble of neighboring aminoacids, than judging it by its position
within an alignment.
This spatial eﬀect of charges can be measured by the electrostatic potential, which is
directly related to the charge density as stated by Poisson's equation, and can be approx-
imated by numerically solving the Poisson-Boltzmann equation (PBE). The electrostatic
potential describes the interaction between atoms A and B as electrostatic interaction
energy:
Eelec = φA(~rB) · qB
where φA(~rB) is the electrostatic potential of atom A at position ~rB of the charge qB
of atom B.
Using the electrostatic potential of the V3 loop to discriminate between R5 and
X4 viruses, combines information of charges and spatial orientation by direct relation.
Furthermore, the electrostatic potential already considers eﬀects of local interaction of
charges. A handful of computer programs are capable of numerically solving the Poisson-
Boltzmann equation, which relates the electrostatic potential φ, the charge density ρ and
the dielectric constant ε at position ~r as follows:
Poisson's equation directly relates the electrostatic potential φ to the charge density
ρ, where ε0 is the charge permittivity in vacuum:
∇2φ(~r) = −ρ(~r)
ε0
Here, ∇2 combines the gradient (∇) and divergence operators (∇·) and can be written
as
∇ · (ε(~r)∇φ(~r)) = −ρ(~r)
ε0
where the gradient operator (innermost ∇) represents the direction of propagation of
the potential, damped by the permittivity of the medium ε(~r). The divergence operator
(outer ∇·) determines whether the electric ﬁeld is inbound or outbound.
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Poisson's equation can thus be rewritten as
−ε0∇ · (ε(~r)∇φ(~r)) = ρ(~r)
Poisson's equation only considers shielding of charges by dielectric constants (ε). To
account for mobile ions in solution the Poisson-Boltzmann equation adds monovalent
mobile ions (e−/e+) to determine charge density:
−ε0∇ · (ε(~r)∇φ(~r)) = ρ(~r) + ne+ − ne−
Based on the theory that positive ions are more probable to reside in regions of negative
potential and vice versa, shielding of charges is modeled by a Boltzmann distribution of
ions based on the local electrostatic potential
n±(~r) = n∞e
±eφ(~r)
kBT
where n±(~r) is the ion number density at position ~r and n∞ is the ion number density
where φ(~r) = 0. Finally Poisson's equation becomes the Poisson-Boltzmann equation
−ε0∇ · (ε(~r)∇φ(~r)) = ρ(~r)− 2en∞ sinh( e(φ(~r))kBT )
The electrostatic potential φ can be calculated for any given coordinate ~r. Here, we
are especially interested in a set of φ around diﬀerent V3 loops, to serve as input for our
machine learning eﬀorts.
Rather than deriving a rule-based prediction from the electrostatic potential data,
we applied machine learning to the problem. Machine learning algorithms are capable
of learning complex interactions, like correlations between diﬀerent variables, or here:
the electrostatic potential at diﬀerent coordinates and the property of being X4- or R5-
tropic. This model can then be used to classify new V3 loop sequences with unknown
tropism. The data vectors, describing the loop, used for training of a model, as well
as future classiﬁcation have to be of constant length and format. In the case of the
electrostatic potential of V3 loops, which is a continuous quantity, the challenge was
to deﬁne a representative set of φ-values. Two requirements had to be fulﬁlled. One,
the set of values had to explain diﬀerences in tropism. Two, they had to be available
for every existing V3 loop. For that case we devised the concept of the electrostatic
hull. The electrostatic hull represents a set of N points in space surrounding the V3
loop structure. The common feature of the points is their equal minimum distance from
the structures solvent-accessible surface (SAS). At each point a discrete value for the
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electrostatic potential φ can be calculated. The hull fulﬁlls one important criterion,
namely that the same set of points can be derived from every V3 loop structure. This is
ensured by choosing the hull wide enough so that every atom of every natural V3 loop
structure can be comfortably embedded (Figure 2.4).
Figure 2.4: The electrostatic hull. The electrostatic hull consists of a set of points with
an equal distance to the solvent-accessible surface of the V3 loop. At each
point a discrete value for the electrostatic potential φ has been calculated.
The hull is wide enough to embed every modeled V3 loop structure. Left:
Hull surrounding the template V3 loop used for modeling of V3 sequences
with unknown structure (PDB: 2B4C). Right: Electrostatic hull embedding
various V3 loop model structures. No atom penetrates the hull.
The fact that the hull is merely a set of coordinates above the V3 loop surface, enables
one to speciﬁcally determine the electrostatic potential at these coordinates for every
modeled loop structure. This is done by superimposing the modeled structures to the
template structure from which the hull was deﬁned earlier. This results in a close to
identical relative orientation of the coordinates of hull and V3 model backbone. The
diﬀerent electrostatic potential calculated at the hull, caused by the distinct side chain
composition of V3 loop models, can then be used to learn the discriminating features of
the two classes, R5 and X4, by means of machine learning. Because of the combination
of spatial information from homology models and the electrostatic potential at a set of
coordinates, the electrostatic hull is a structural descriptor.
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2.1.4 Sequence Descriptor: The Hydropathy Scale
In previous attempts to predict co-receptor usage, various groups have had considerable
success by using sequence information only, applying diﬀerent machine learning or scoring
methods [117, 65, 111]. To our knowledge random forests have not been used for co-
receptor usage prediction based on V3 loop sequence as a descriptor. In addition to the
structural, electrostatic potential descriptor, we were eager to test the performance when
using a more basic descriptor, based solely on the V3 loop sequence. Machine learning
algorithms often work with sequences of numerical values, thus, protein sequences have
to be translated prior to model training. A simple translation scheme would be the
use of one unique value for every aminoacid. For most cases, one could imagine 20
values, representing the 20 crucial aminoacids. Similarity between properties is modeled
by the numerical diﬀerence of values. Thus, properties coded by values with small
diﬀerences are more similar to each other than those with larger diﬀerences. Using
the previously suggested coding scheme of unique values based on the aminoacid name
will quickly produce problems. Performance of trained models would vary considerably
depending on chosen pairs of aminoacid ↔ n. This problem can be solved by relating
not the aminoacids per se to numerical values, but rather coding their physicochemical
properties. There may be no similarity between lysine and arginine considering their
names, but both carry positively charged sidechains. The positive net charge makes
both aminoacids similar by the charge property. The same can be said for aspartate
and glutamate, both side chains are negatively charged. When assigning numerical
values to these aminoacids, the sum of numerical diﬀerences within each group should be
minimized, whereas the diﬀerence between the groups should be maximized. This is only
a simple example of how aminoacids can be reasonably coded into numerical values, so
called numerical descriptors. In fact, a huge number of descriptor sets have already been
published [66], based on properties such as molecular weight, charge, solubility, secondary
structure preferences, or hydropathy. The hydropathy scale by Kyte and Doolittle [76]
assigns a numerical value to each aminoacid, reﬂecting its hydrophilic or hydrophobic
character, as determined by the authors. In general, more hydrophilic aminoacids are
assigned more negative values, while more positive values are assigned to hydrophobic
aminoacids. This scale has been successfully applied in protein classiﬁcation problems.
Heider et al. have been able to predict small GTPases and the susceptibility to the HIV
maturation inhibitor berivimat, based on the aminoacids sequences translated using the
hydropathy index [50, 52]. Additionally to the translation of aminoacids sequence into
the Kyte-Doolittle hydropathy index, we used a normalization procedure to ensure a
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constant length of translated sequences, a prerequisite of the random forest algorithm.
Alternatively, sequences could be aligned to a reference sequence, however, the problems
arising from sequence alignments have already been discussed (see Section 2.1.3). The
normalization procedure is described in detail in the materials and methods section.
The normalized V3 loop sequences are referred to as sequence descriptors. The resulting
machine-learning model will be referred to as the hydrophobicity model.
2.2 Materials and Methods
V3 sequence training data For the training of the tropism prediction models, V3
loop sequences with experimentally determined co-receptor usage were taken from the
Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/). The web site search
interface allows ﬁltering based on co-receptor usage, thus, three searches were performed:
one for each of the classes R5, X4, and R5X4. Additional ﬁltering criteria oﬀered by the
search interface were used as follows. Virus type was set to HIV-1, while no subtypes were
excluded. V3 was set as the genomic region. Problematic sequences, classiﬁed as those by
the HIV Sequence Database were excluded. For the R5X4 class, only sequences of clonal
nature were included, thus removing sequences with a dual/mixed tropism annotation.
The tropism of a sequence was considered doubtful if the same sequence occurred in
more than one tropism class. As a consequence, these sequences were removed from
all classes. Sequences occurring more than once in the same class, were reduced to one
single copy. Sequences shorter than 30 aminoacids were removed to reduce the noise in
the dataset. The longest sequences consisted of 38 aminoacids. Furthermore, sequences
with obvious errors, such as frameshifts or ambiguous residues were also excluded from
the set. After application of the stated ﬁltering criteria, the training set consisted of
1151 R5 sequences, 166 X4 sequences and 34 R5X4 sequences. 284 of these sequences
contained insertions or deletions (17% of R5, 51% of X4, 10% of R5X4). We published
the datasets were published as supplementary material with the here and can be accessed
at http://dx.doi.org/10.1371/journal.pcbi.1000743.
Clinical Sequences Diﬀerent sets of V3 loop nucleotide sequences were kindly pro-
vided by Saleta Sierra-Aragon and Rolf Kaiser from the Institute for Virology in Cologne,
Germany, as well as Alexander Thielen from the Max Planck Institute for Informat-
ics in Saarbrücken. Additional V3 loop sequences were collected from the literature
[43, 67, 98, 58]. From this collective set, sequences containing ambiguous nucleotides
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were removed and the remaining sequences were translated into aminoacid code and
subsequently ﬁltered, using the same criteria as for the V3 sequence training data, de-
scribed above. The ﬁnal set of clinical sequences consisted of 381 sequences in total,
with 132 X4 and 249 R5 sequences.
Homology modeling of V3 loops Homology modeling of all V3 loop sequences was
done using the Modeller software [125], version 9.6. The V3 loop of the X-ray structure
of gp120 bound to CD4 and an antibody (PDB: 2B4C) by Huang et al. [57] was used
as template. Each sequence to be modeled was ﬁrst pairwisely aligned to the template
sequence. The initial model was then built allowing only for optimization at regions
of insertions or deletions. In the following optimization step sidechain positions and
rotations were energy minimized to resolve possible sterical problems. The root mean
square deviation over all 1351 V3 models used for training was 0.85 Å with a standard
deviation of 0.18 Å.
Homology Modeling and Electrostatic Potential of Co-receptors Models of
both, CCR5 and CXCR4, were built using the crystal structure of bovine rhodopsin
(PDB: 1GZM), chain A [80], identiﬁed by PSI-Blast [2]. Initial sequence alignments were
taken from a PSI-Blast and manually corrected to accommodate transmembrane areas.
Ligands and water molecules were removed from the template. During the modeling
process, post-translational modiﬁcations, like sulfated tyrosines were not considered.
The following steps were equally applied to the modeling of both co-receptors. Sidechain
replacement, according to the alignments generated was performed by SCWRL [14].
Sterical clashes were removed with MOBY [55]. Loop regions were modiﬁed by manually
resolving gaps or inserts through addition or removal of aminoacids. Next, modiﬁed
regions were subject to simulated annealing (5 ps) and energy minimization using MOBY.
Finally, the complete models were fully energy minimized. The modeling protocol can
be found in Wolf et al. 2008 [164]. The electrostatic potential of the co-receptor models
were calculated using APBS version 1.0 [5] with default settings.
Electrostatics hull Calculation of the electrostatic potential around a given V3 loop
structural model was performed by solving the Poisson-Boltzmann equation with the
Adaptive Poisson-Boltzmann Solver  APBS (Version 1.0.0) [5]. Charges and radii of V3
loop atoms were assigned by PDB2PQR (Version 1.3.0) [28], according to the AMBER
forceﬁeld speciﬁcations. Parameters of the Poisson-Boltzmann equation were used as
follows: ionic strength was set to zero, dielectric constants of protein and solvent were
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altered to optimize prediction accuracy resulting in equal values of protein = solvent = 5.0.
A temperature of 310 K was used and a single Debye-Hückel sphere was considered as
boundary condition to solve the non-linear Poisson-Boltzmann equation. A cubic grid
consisting of 333 grid points, with a grid spacing of 3 Å was centered over each V3 loop
structure. For the construction of the electrostatic hull, the solvent-accessible surface
of the template V3 loop structure was used. In addition to the grid containing the
electrostatic potential, APBS produces a second grid with information on the protein
solvent accessible surface. This surface is approximated using a solvent probe of r = 1.4
Å. Both grids are congruent and thus allow conclusions on the electrostatic potential on
the SAS. In order to ensure complete embedding of every possible V3 loop structure in
the electrostatic hull, the calculated surface was extended further into the solvent. The
amount of extension was varied by n = 1, 2, 3 times the grid spacing distance, resulting
in three hulls, equidistant from the V3 loop SAS at 3 Å, 6 Å, and 9 Å. All hulls were
capable of completely embedding V3 structure models, but the hull at 6 Å yielded the
best results.
Random Forests Random forest analyses were performed with the package random-
Forest [82] of R [115]. The out-of-bag error was used to estimate errors; a ten-fold
external crossvalidation performed to test the robustness of error estimation yielded
equal results. For ROC analyses the ROCr package [137] of R was used. True positive
rates of the form a± δ given in the text are averages a over 10 random forest trainings
with ±δ marking a 95% conﬁdence interval estimated with a t-distribution.
Patient-wise Crossvalidation Scheme Sequences were ﬁrst grouped by the inter-
nal patient identiﬁcation numbers, so that each group contained every sequence of one
single patient. Model performance was then evaluated by a leave-one-patient-out cross-
validation scheme. One round of model training was performed per patient, using every
sequence not associated with the speciﬁc patient. Tropism of the sequences left out were
subsequently predicted and prediction results were used for evaluation.
Normalization Procedure In order to cope with the varying sequence length and
provide a ﬁxed length of input data for the machine learning methods applied, we used
a length normalization procedure, previously described by Heider et al. [50, 51]. To
normalize a signal (i.e. a sequence of descriptor values) of length N to a new target
length M, one has to ﬁrst interpolate the signal and then choose M equally distanced
values from the interpolated signal. Any common method like simple linear, cubic spline,
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periodic spline, or natural spline interpolation can be used. The linear interpolation
method has been shown to yield the best results in terms of predictive performance for
various protein classiﬁcation problems (Heider et al., unpublished) and is exclusively
used throughout this work. For the linear interpolation, the y-value for a given x-value
in the interval [xn, xn+1] is given by
y = yn + (x− xn) yn+1−ynxn+1−xn .
Here the x-value and y-values describe the newly calculated sequence position and
feature value, respectively. The signal of target length M can now be acquired by calcu-
lating and concatenating the y-values of M equidistant x-values along the interpolated
signal from x0 to xN , with
[xm,xm+1]
[xn,xn+1]
= M
N
.
Model Performance Analysis Performance measures of sensitivity, speciﬁcity, ac-
curacy, true positive rate (TPR), and false positive rate (FPR) were calculated by
TPR = sensitivity = TP
TP+FN
specificity = 1− FPR = TN
TN+FP
accuracy = TP+TN
TP+TN+FP+FN
with TP: true positives, FP: false positives, FN: false negatives and TN: true negatives.
Receiver Operating Characteristics (ROC) curves and the corresponding AUCs were
calculated with ROCr [137]. All performance values of the form a± δ given in the text
are averages over ten random forest trainings with ±δ marking a 95% conﬁdence interval
estimated with a t-distribution. Crossvalidation schemes applied during training varies
and is mentioned for each case.
Comparisons With Other Methods The performance of the 11/25 and 11/24/25
rules were calculated manually after alignment to the HXB2 reference V3 loop se-
quence. Predictions for tropism prediction by geno2pheno and PSSM the respective
web-interfaces were used (see Table 1.2) with standard settings.
2.3 Results
2.3.1 Prediction of Tropism Based on the Electrostatic Potential
To train a machine learning model based on the electrostatic potential information of
V3 loops, V3 sequences with known tropism were acquired from the Los Alamos HIV
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Sequence Database (http://www.hiv.lanl.gov/), as described in detail in the Ma-
terials and Methods section. After ﬁltering, the remaining set contained 1351 unique
sequences. The majority (85%) of these originated from Europe (37%), Africa (34%)
and North America (14%). 55% of sequences are of subtype B, most common in Europe
and North America, followed by subtypes C (17%) and D (10%) the common subtypes
in Southern and Eastern/Central Africa, respectively (see Figure 2.5). The majority
of European sequences have been collected in the Netherlands, Belgium, Sweden, and
Switzerland. The set contains no sequences collected in Germany.
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Other
S. America
Number of sequences
0 100 200 300 400 500
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Figure 2.5: Origin (left) and subtypes (right) of training sequences.
All V3 loop sequences were subject to homology modeling based on the V3 crystal
structure loop by Huang et al. [57]. The structural data on V3 is very limited, and
from the experimentally determined structures, as well as in-house molecular dynamics
simulations (data not shown) a great ﬂexibility of the loop can be deduced. These facts
combined leave no doubt as to the probable errors made by modeling over one thousand
loops with varying sequences based on a single template. The central assumption jus-
tifying this approach, however, is that mapping of electrostatic potential values to one
possible structure is suﬃcient to provide a basis for a separation of X4- and R5-tropic
variants. The modeling procedure and minimization process is described in Materials
and Methods.
The electrostatic hull was then created, based on the template structure. The solvent
accessible surface was used as initial hull and extended into the solvent. Each extension
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step increased the distance of the hull surface from the solvent-accessible surface by 3
Å. To assess the impact of diﬀerent hull volumes on the model performance multiple
hulls were generated by varying the amount of extensions steps (see Figure 2.6). The
best performance was achieved using a hull based on two extension steps, accounting for
the electrostatic potential 6 Å above the solvent-accessible surface. In the following, the
performance of hull sizes other than 6 Å are not shown.
Figure 2.6: The electrostatic hull with varying volume. Here, the electrostatic
hull is shown with varying extensions steps. The distance from the V3 loop
solvent-accessible surface to the hull ranges from 3 Å, over 6 Å to 9 Å (from
left to right).
The electrostatic hulls were used to construct a random forest model using the ran-
domForest Package [82] for R. The training methods takes a table as input, relating a
response variable (the tropism) to a set of feature variables (the electrostatic potential).
The structure of training data table is shown in Table 2.1.
The clinical interest of co-receptor usage prediction is the identiﬁcation of CXCR4-
using viruses. In that regard, both X4 and R5X4 viruses belong to the same class.
Consequently, all R5X4 viruses were labeled as X4 viruses. In total, 10 random forest
models were built, each consisting of 500 decision trees. At each tree nodem = b√642c =
25 variables were used for splitting. The OOB estimate of error averaged over all 10
models was 0.0472±0.0002. The error rates for the respective classes were 0.0174±0.0002
for R5 and 0.2198± 0.0007 for X4. Thus, the estimated error rate for the X4 sequences
is over 10 times higher than that of the R5 rate.
The internal estimation of the error rate considers the results of the OOB data eval-
uated by the trees. A tree can only make a binary decision. A class, predicted by a
decision tree as a single classiﬁer, is either R5 or X4. The result of the complete forest
as an ensemble classiﬁer, is the fraction of votes for a speciﬁc class, thus a numeric value
between 0 and 1. Usually, the class with the most votes, as in decisions by single trees,
is accepted as the predicted class. In the case of two classes, a majority of at least 50%
of the votes seems reasonable. A cutoﬀ between the classes is drawn at 50% of votes,
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Table 2.1: Training data structure for the electrostatic potential model. Each
line holds the electrostatic potential values of the electrostatics hull in lin-
earized form. In total 1351 V3 loop models were used, with 642 φ-values.
V3 Sequence Tropism φ1 φ2 φ3 ... φ642
V 31 X4 -0.0019 12.7167 8.5402 ... 15.7409
V 32 X4 0.3707 17.1011 13.5197 ... 12.6159
V 33 X4 -0.0933 17.2641 10.3534 ... 0.1495
... ... ... ... ... ... ...
V 3201 R5 0.0539 0.8321 0.4180 ... 10.6525
V 3202 R5 0.6183 14.6741 8.5445 ... -0.0833
V 3203 R5 0.0307 0.7533 0.4082 ... 1.5988
... ... ... ... ... ... ...
V 31351 R5 0.1543 0.5784 0.0183 ... 1.7093
or a fraction of 0.5; this cutoﬀ can be altered. Hence, when setting the cutoﬀ to above
or below 0.5 one shifts the outcome in favor of one class, over the other. The cutoﬀ has
a clinical relevance, as it can be shifted to tune the prediction to be more conservative
or more liberal, depending on the risk or value of treatment. Figure 2.7 shows the pre-
dictions made for the X4 sequences (orange) and the R5 sequences (blue) on the x-axis.
The prediction value represents the fraction of X4 positive votes. The class predictions
range from 0 (no X4 votes → R5) to 1 (all X4 votes → X4). Clearly, X4 sequences are
clustering around high fractions of X4 votes. The opposite is true for the R5 sequences.
The dotted line represents the standard cutoﬀ of 0.5. With this cutoﬀ a sequence with
less than 50% of X4 votes is classiﬁed as an R5 virus. Notably, the X4 predictions of X4
sequences are more spread out than for the R5 sequences. This trend is visualized by
the density plot on the top right of Figure 2.7. Interestingly, no X4 sequence has a pre-
diction probability of 1.0. Thus, no X4 sequence was unanimously classiﬁed as such by
all decision trees of the forests. In contrast, many R5 sequences have an X4-probability
of zero, indicating recognition without errors.
Prediction accuracy, in this case, is not a fair measure as the accuracy measures the
fraction of positive predictions over all sequences. In our sequence we have around six
R5 sequences for every X4 sequence An accuracy of 83% can be achieved by simply
setting the cutoﬀ to 0, thus predicting every sequence to be R5. A better measure of
performance is to observe the false positive rate against the true positive rate, varying
the cutoﬀ. Both estimators are rates, and do not take in account the absolute, but the
relative number of predictions for the classes. Figure 2.8 shows a receiver operating
53
2.3. Results
2
0
1
2
3
4
5
6
7
D
en
si
ty
X4
R5
ll ll
ll l l
ll l l
llll
l lll
ll ll
ll ll
l ll l
l ll
l lll
ll l l
l ll l
l l ll
l l ll
ll ll
lll l
l l ll
l l ll
l l ll
ll ll
l ll l
lll l
l l ll
ll ll
ll ll
ll ll
ll l l
ll l l
l ll l
l lll
ll ll
l ll l
ll l l
lll l
l lll
ll ll
ll ll
ll ll
lll l
l lll
l l ll
l l ll
l lll
l l ll
l l ll
l ll l
ll ll
ll ll
ll ll
l l l l
0
50
10
0
15
0
20
0
X4
 s
eq
ue
nc
e
lll l l llll l l lll ll lll
ll ll l l lll l llll l l
l lll lll l ll ll ll ll ll ll
ll ll ll lll l lll ll llll l l
ll ll lll ll ll ll l
l l ll llll lll ll ll ll l l
lll lll ll ll l ll ll lll
ll llll l l lll ll lll l l lll
lll ll ll ll l ll lll l l ll l
ll l ll l lll ll ll llll
l ll ll ll l lll ll ll l lll
l ll l lll ll lllll llll l l
l l ll lll ll lll ll lll l l
l ll llllll ll llll llll ll
l l lll l l ll lll ll l llll ll
lll lll lllll lll l ll ll
ll l ll ll ll l l l lll lll ll
l lll l ll ll lll lll ll l l
lll lll lll lll ll lll lll
l llll ll l ll lllll llll lll
ll ll l l lll l l lll ll l
ll lll l ll l ll ll ll l l l
ll ll l ll ll ll lll ll l
llllll llll l lll ll l ll
lll lll l llll l lll l ll l
l lll ll ll lll ll lllllll
ll lll l l ll lll l lll
l lll ll ll llll l l
ll l l ll lll ll l l lllll l
ll ll ll l ll ll l lllll ll l
ll l lll lll llll l lll
l lll lll l l lll l ll ll l
l ll ll ll ll ll l lllll l
l lll lll l ll llll ll l l
llll l l ll lll l l l llll
l lll ll l lll ll l l llll l
llll ll llll llll lll
l llll ll llllll llll l l
l lll ll ll l ll ll lll ll llll
l ll l ll lll lll ll llll
ll l llll l llll lll l
lll l ll l llll ll llll ll l
l l ll ll lll ll l ll ll ll l ll
ll l llll ll lllll ll l l ll
lll ll l lll lll l ll l lll ll
l l lll ll l l
0.0 0.2 0.4 0.6 0.8 1.0
0
20
0
60
0
10
00
Predicted X4 probability
R
5 
se
qu
en
ce
l
l
l
Figure 2.7: Distribution of predictions from the electrostatic potential model.
The plot shows the distribution of prediction for R5 (blue) and X4 (orange)
sequences made by the electrostatic potential model. Predictions were sub-
ject to an internal crossvalidation as described in Section 2.1.2.
characteristic (ROC) curve. This curve plots the true positive rate (TPR) against the
false positive rate (FPR), for a cutoﬀ ranging from 0 to 1. Given a perfect classiﬁer
and an error-free training and test set, the ROC curve would reach a combination of
TPR = 1.0 and FPR = 0.0. A common measure in combination with ROC curves is to
integrate the area under the ROC curve (AUC) [38]. The AUC can vary between 0 and
1, with a random classiﬁcation resulting in an AUC of around 0.5. Performance measures
calculated in the following were averaged over ten independently trained models. The
electrostatic potential classiﬁer exceeds a TPR of 0.9 at a FPR of 0.1, for a cutoﬀ of
0.19. This means that while correctly predicting over 90% of the X4 sequences, less than
10% of R5 sequences are misclassiﬁed. The electrostatic potential model has an AUC
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of 0.957±0.001. For comparison reasons, the performance of the 11/25 and 11/24/25
rules on the same sequence set are shown. Figure 2.8 supports our initial theory that
a classiﬁer trained by machine learning and inspired by the 11/25 and 11/24/25 rules
could outperform these simple models. This was possible by taking into account a ﬁner
resolution and more detailed representation of electrostatics by the electrostatic hull.
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Figure 2.8: ROC curve of the electrostatic potential classiﬁer. The plot shows a
receiver operating characteristic (ROC) curve. The curve is drawn by calcu-
lating the true positive (y-axis) and false positive (x-axis) rates of the model
predictions for a varying cutoﬀ between the X4 and R5 classes. Predictions
were subject to the internal crossvalidation of the random forest algorithm
as described in Section 2.1.2.
The dataset of V3 sequences used for model training contains sequences that are
originating from the same patient. It is plausible that these sequences are likely to have
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a higher similarity to each other than to other sequences within the dataset. Considering
this similarity of sequences, one can deduce a source of bias, introduced by using a leave-
one-sequence-out crossvalidation. To measure the eﬀect of sequences originating from the
same patient on the overall structure of the training data, pairwise alignment scores were
calculated between all sequence pairs. For each sequence the highest alignment score to
any other sequence within the set was recorded. The distribution of distances to the
nearest neighbor show how well sequences within a set are connected to other sequences.
A set of very similar sequences will result in many high alignment scores, a very diverse set
will probably include lower alignment scores, due to sequences with smaller similarities
to other sequences. Figure 2.9 shows the degree of similarity between all sequences used
for model training in orange. The same similarity measure for a reduced sequence set,
only containing a single sequence per patient, is shown in blue. There is a clear diﬀerence
between the two distributions. While most sequences within the complete training set
have at least one very similar sequence neighbor (high alignment score), the distribution
is signiﬁcantly shifted towards lower similarity in the reduced training set. This can
be explained by the removal of similar sequences originating from the same patients.
A higher inner similarity of training sets probably aﬀects the performance in a simple
crossvalidation. For every sequence left out during a crossvalidation iteration, a very
similar sequence, possibly from the same patient, is used for model training, raising the
chance of a successful classiﬁcation. Under these conditions, this simple crossvalidation
scheme should not be used, because its result tells little about the performance for
genuinely new sequences.
To test this hypothesis and to quantify the eﬀect, we developed a leave-one-patient-out,
or patientwise crossvalidation scheme. Details are found in the Materials and Methods
section of this chapter. Using this scheme, the whole set of sequences originating from a
single patient are left out of the training set and predicted by the trained model.
Figure 2.10 shows a direct comparison of the performance of the electrostatic poten-
tial model with a sequencewise crossvalidation and a patientwise crossvalidation. The
results clearly show a diﬀerence in performance, both in terms of true positive rate and
false positive rate. The performance estimation based on the internal crossvalidation
scheme of the random forest algorithm (orange) thus seems to be biased by sequences
originating from the same patient. At a false positive rate of 0.05, the diﬀerence in
sensitivity is around 0.1. For smaller FPR, this diﬀerence is even larger. Using the
patientwise crossvalidation, the AUC drops to 0.934 ±0.001. However, despite the more
conservative performance estimation, the ESP classiﬁer still performs better than the
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Figure 2.9: Sequence similarities as alignment distances. The density plots show
the distribution of maximum alignment scores of all sequences within the
complete sequence set against each other (orange), and for a reduced set
containing only one sequence per patient (blue). The distributions show that
in the complete set, the majority of sequences have at least one very similar
sequence within the same set, as can be seen from the high alignment scores
of 95 to 100. In the reduced set, the distribution is shifted towards lower
alignment scores, meaning that, on average, sequences are less similar to
their nearest sequence neighbor.
11/25 and 11/24/25 rules with an increased true positive rate of around 0.09 and 0.16
at the respective false positive rates, indicating that more sophisticated methods, like
machine learning are able to extract more information from the charges of the V3 loop
than alignment- or rule-based models.
Figure 2.11 shows the error rate of the model for the two classes X4 (blue) and R5
(orange) for diﬀerent cutoﬀ levels. On the left side, the error rates are estimated from the
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Figure 2.10: Comparison of performance based on the crossvalidation scheme.
The plot compares the performance of the electrostatic potential model
using the sequencewise (orange) and patientwise (blue) crossvalidation
schemes. The sequencewise crossvalidation seems to overestimate the model
performance, due to multiple sequences originating from the same patients.
internal sequencewise crossvalidation performed by the random forest algorithm. With
the previously reported bias of that crossvalidation scheme due to sequences originating
from the same patient, the error rates are higher when using patientwise crossvalida-
tion (right side). The optimal cutoﬀ depends on the importance one gives to either of
the classes. Currently, the only co-receptor antagonist approved for treatment in both
the United States and Europe is maraviroc. The MOTIVATE 1 and MOTIVATE 2
studies performed to asses the virologic and immunological eﬃcacy of maraviroc have
shown that maraviroc in combination with other drugs (NRTI, NNRTI, PI) was able to
reduce signiﬁcantly reduce the viral load of patients with non-detectable CXCR4 virus
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Figure 2.11: Comparison of cutoﬀs based on the crossvalidation scheme. The
plots shows the rate of errors made for the respective classes X4 and R5
using a sequencewise (left) and patientwise crossvalidation (right).
(see Section 1.4.3). Patients with detectable CXCR4 virus were oﬀered to participate
in a parallel study and receive the same treatment. Although these patients did not
beneﬁt from the treatment of maraviroc, no rapid decline in CD4 counts of faster dis-
ease progression were witnessed [124]. In a recent follow-up study conducted by Pﬁzer,
15 patients from the MERIT study who experiences therapy failure due to co-receptor
switches were analyzed. All patients were reported to respond well to subsequent ther-
apy, showing no signs of adverse clinical consequences [113]. These ﬁndings suggest
a more liberal CXCR4 detection strategy applying higher cutoﬀs to decrease the false
positive rate, thus including more patients for treatment with maraviroc. On the other
hand, increasing the cutoﬀ will result in an increased rate of eﬀective maraviroc treat-
ments. A widely accepted method of choosing the prediction cutoﬀ is to look at the
results in false positive rates. The German Recommendations for the Determination of
Co-receptor Usage [26], for example, recommend choosing a cutoﬀ resulting in a FPR
of 20% for patients with many therapy options, and a more liberal cutoﬀ resulting in
12.5% FPR for patients with limited treatment options (Figure 2.11 shows that FPR is
the R5 prediction error rate). When evaluating the performance with the patientwise
crossvalidation scheme (right curves), an FPR of 12.5% and 20% would approximately
be achieved for the cutoﬀs 0.17 and 0.1.
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2.3.2 Prediction of Tropism Based on the Hydropathy Scale
Prediction of co-receptor usage based on the electrostatic potential of V3 loops relied
on homology modeling of the V3 loop structure. The electrostatic potential above the
solvent-accessible surface is directly related to the loop sequence, but is also largely de-
pendent on the orientation, size, and charge of aminoacid sidechains. These attributes
are of structural nature and considered by the electrostatic hull model. The dimension-
ality of a sequence descriptor is much lower, compared to that of a structural descriptor.
For instance, changes in sidechain interaction due to their conformation are not mod-
eled. To test the performance of a reasonable sequence descriptor, a second random
forest model was built, based on the same set of V3 loop sequences, translated accord-
ing to the Kyte-Doolittle hydropathy scale and normalized to a constant length of 38.
The input table for random forest generation relates the known classes of tropism to
the translated sequences. The data structure used for training is schematically shown in
Table 2.2.
Table 2.2: Data structure of training data used for the hydrophobicity model.
V3 Sequence Tropism h1 h2 h3 ... h38
V 31 X4 0.7777 0.4510 0.0684 ... 0.7777
V 32 X4 0.7777 0.4798 0.1369 ... 0.7777
V 33 X4 0.7777 0.7021 0.0378 ... 0.7777
... ... ... ... ... ... ...
V 3201 R5 0.7777 0.4606 0.0912 ... 0.7777
V 3202 R5 0.7777 0.4510 0.0684 ... 0.7777
V 3203 R5 0.7777 0.9759 0.2162 ... 0.7777
... ... ... ... ... ... ...
V 31351 R5 0.7777 0.4510 0.0684 ... 0.7777
The prediction model based on hydropathy scale consisted of 500 decision trees, each
tree using m = b√38c = 6 variables at each node for splitting. In total, ten random
forests were generated to determine the average performance based on a patientwise
crossvalidation. Figure 2.12 shows the cutoﬀ-dependent error rates for the classes R5
and X4. In comparison to the error-curves of the electrostatic model (Figure 2.13), the
R5 curve is slightly shifted towards lower cutoﬀs. The cutoﬀs achieving false positive
rates of 12.5% and 20% are 0.12 and 0.06, respectively. The error-rate of the X4 class
reaches a lower level earlier than for the electrostatic potential model, but seems to
maintain a higher level at low cutoﬀs.
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Figure 2.12: Cutoﬀ-dependent error rate of the hydrophobicity model. The
plots shows the rate of errors made by the hydrophobicity model for the
respective classes X4 and R5 using a patientwise crossvalidation.
The ROC curves in Figure 2.13 allow comparison of the performance of the electro-
static and hydrophobicity models. None of the models is superior to the other, with
the electrostatic model having an advantage at higher false positive rates and the hy-
drophobicity model dominating at lower FPRs. This insight leads to the conclusion that
both models could be combined to improve the overall performance. When comparing
the two false positive rates recommended by the German Guidelines, the electrostatic
potential model seems to perform better. While both models reach the same TPR at a
FPR of 12.5%, the TPR of the hydrophobicity model is approximately 3% lower at the
20% FPR than the ESP model. The AUC of the hydrophobicity model is 0.930 ±0.001.
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Figure 2.13: Performance comparison of ESP and hydrophobicity classiﬁers.
ROC curves of the electrostatic potential and hydrophobicity models, based
an the patientwise crossvalidation scheme. For this sequence set, neither
model seems to be superior to the other, the electrostatics model performing
better at higher, the hydrophobicity better at lower FPR.
2.3.3 Fusion of Electrostatics and Hydrophobicity Models
The previous results have shown that machine learning models based on diﬀerent de-
scriptors are equally able to classify HIV-1 viruses into R5 and X4 variants simply by
evaluating their V3 loop sequences. Two models were trained. The ﬁrst, based on
the electrostatic potential on a virtual hull surrounding the loop, can be regarded as a
structure-based descriptor. The second model, using the hydropathy scale of Kyte and
Doolittle relies on the discretized aminoacid sequence of a V3 loop, excluding any struc-
tural information. Random forests are ensemble classiﬁers, a collection of independent
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decision trees voting on the class aﬃliation of unknown data, reaching a ﬁnal decision
by majority vote. An ensemble classiﬁer is deﬁned as a collection of single classiﬁers.
These classiﬁers can be of any kind or complexity. Decision trees can be used, as seen
in random forests, but even quite complex classiﬁers can be combined into an ensemble
classiﬁer. In theory, one can iteratively create ensemble classiﬁers, based on the votes of
underlying classiﬁer ensembles. This is known as stacking [165]. The performance gain
of combining an ensemble of classiﬁers greatly depends on the underlying descriptors
and combination method used. Combining classiﬁers by means of machine-learning, one
would expect, as a worst case, to see no improvement in performance, as the resulting
model should be able to learn to imitate the best single classiﬁer in the ensemble. A
simple example of a case where no performance improvement is expected is the combi-
nation of multiple classiﬁers of the same set up, based on the same descriptor. In this
naïve case, every single classiﬁer evaluates the same data under the same circumstances,
thus there is nothing that can be learned from their combination. This changes, once
one combines classiﬁers evaluating diﬀerent aspects on the same data, which is true for
our two previously built models.
The structural classiﬁer, based on the electrostatic hull has a diﬀerent perception of the
data than the hydrophobicity-based sequence classiﬁer. As a consequence, it is possible
for the two classiﬁers make discordant predictions for the same V3 sequence. This was
already indicated by the comparison the ROC curves of the two models. None of the
models was superior to the other, each dominating the other at diﬀerent cutoﬀ levels
(Figure 2.13). The assumption is further veriﬁed by correlating predictions of the two
classiﬁers. Figure 2.14 shows a scatterplot of all sequences in a prediction plane. Each
point in the plot represents a single sequence of the dataset placed according to the
predictions made by the electrostatic potential classiﬁer (x-axis) and the hydrophobicity
classiﬁer (y-axis). The prediction can be understood as a probability of a sequence being
X4. Accordingly, R5 sequences (orange circles) are clustered in the lower left corner,
while CXCR4 using virus variants (X4 and R5X4) cluster in the upper right corner. The
majority of sequences have diﬀering predictions from the two classiﬁers. The remaining
corners, upper-left and lower-right are regions, where predictions from the two classiﬁers
are contradictory. Although no sequences are found there, some sequences are closer to
these conﬂicting corners than to either of the R5 or X4 corner. For these sequences it
is hard to make a decision. Intuitively, one could couple the predictions using simple
mathematical operators like minimum or maximum. Choosing the smaller, or larger of
the values as ﬁnal decision. Another possible solution would be to ﬁnd a linear two-
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Figure 2.14: Scatterplot of electrostatic model vs. hydrophobicity model votes.
The plot shows the results of both prediction models on each of the V3 loop
sequences of the training data set. The votes are results of the patient-
wise crossvalidation scheme. Concordant votes of both models are found in
the lower left and upper right corners, while the sequences with discordant
predictions spread towards the lower right and upper left corners.
dimensional separator function, dividing the prediction plane into an R5 and an X4
region. An even more sophisticated and possibly more powerful approach is to learn a
non-linear separator function.
In order to determine the eﬀect of a sophisticated separator function, another random
forest was trained and compared to the simple separator functions minimum (min), max-
imum (max) and multiplication (mult). In the spirit of stacking the prediction results
of the two independent classiﬁers were used as input for the new second-level model.
The goal was to ﬁnd an optimal second-level classiﬁer to interpret the individual predic-
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Table 2.3: Data structure of training data used for the combined model.
V3 Sequence Tropism pX4(ESP ) pX4(Hydrophobicity)
V 31 X4 0.78 0.30
V 32 X4 0.66 0.96
V 33 X4 0.80 0.79
... ... ... ...
V 3201 R5 0.28 0.11
V 3202 R5 0.10 0.00
V 3203 R5 0.00 0.00
... ... ... ...
V 31351 R5 0.01 0.00
tions and to learn how to classify sequences with discording results. In order to have a
good data basis to the train the second-level random forest, the scatterplot of the two
independent ﬁrst-level predictions was closely examined. The training of ten individual
ﬁrst-level models revealed a standard deviation of predictions of 0.007 and 0.009 for the
hydrophobicity and electrostatic potential classiﬁers, respectively. This variation can be
explained by the the random selection of features during forest generation. The predic-
tion landscape (shown for one set of ﬁrst-level models in Figure 2.14) will, thus, look
slightly diﬀerent when re-training electrostatic or hydrophobicity models.
The simple classiﬁers min (2.1), max (2.2) and mult (2.3) considered the smaller,
larger or multiplied values of the ﬁrst-level predictions, respectively.
pmin = min(pESP , phydrophobicity) (2.1)
pmax = max(pESP , phydrophobicity) (2.2)
pmult = pESP · phydrophobicity (2.3)
The data structure used for training of the second-level random forest is shown in
Table 2.3.
Figure 2.15 shows the ROC curves of the second-level models random forest (RF),
minimum (min), maximum (max) colored in green, red and black, respectively. The
ROC curve of the random forest model (green) shows the superior performance of the
new model over the two ﬁrst-level models (orange and blue). The AUC of 0.95 ±0.001
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Figure 2.15: ROC curves of the diﬀerent second-level classiﬁers compared to
the ﬁrst-level classiﬁers. The second-level classiﬁers seem to generally
perform better than the ﬁrst-level classiﬁers alone, with the exception of
the ESP model at high FPR and the hydrophobicity model at low FPR.
The random forest second-level classiﬁer, however is superior to every other
model for this dataset, using a patientwise crossvalidation.
is signiﬁcantly higher than those of the other models. Although the combined model
seems to slightly outperform the ESP model at the FPR of 12.5% it holds an increase
of TPR of around 5% over both ﬁrst-level models at the FPR of 20%. Remarkably, it
seems that the FPR can be decreased by more than 14% (20% to 6%) while sacriﬁcing
only about 3% of TPR (from 93% to 90%).
The following analyses will examine how the second-level classiﬁers are evaluating
the independent votes of the electrostatic and hydrophobicity model. In comparison
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to the simple classiﬁers min, max, and mult, the evaluation scheme of a sophisticated
model such as the random forest is not intuitive. In order to visualize the prediction
pattern learned by the random forest, a set consisting of all possible pairs of ﬁrst-level
predictions was generated. Each pair was then evaluated by the respective second-
level classiﬁers min, max, mult, and the random forest. The results are prediction
landscapes as shown in Figure 2.16. Each coordinate of a landscape represents a pair
of ﬁrst-level votes. The color at that coordinate encodes the outcome of the second-
level classiﬁer for the speciﬁc ﬁrst-level votes according to the right handed color-keys.
The colors are chosen to visualize the clinically relevant false positive rates (12.5% and
20%) of the models. Enclosed in the green areas lie 80% of all R5 sequences of the
patientwise crossvalidated training data, thus choosing this rigid cutoﬀ to distinguish
between X4 and R5 sequences yields a FPR of 20%. The cutoﬀ enclosing 87.5% of all
R5 sequences (12.5% FPR) combines the green and orange areas. Extending the cutoﬀ
into the blue area will result in more sequences being interpreted as R5. In a clinical
setting this would mean, that more patients would be considered for treatment with
co-receptor antagonists. In turn, one would increase the risk an ineﬀective treatment,
due to misclassiﬁed X4 viruses. Looking at the prediction landscapes of the simple
second-level classiﬁers (min, max, product) one notices the uniform shape of diﬀerent
relevant FPR-classes (green and orange). All of these classiﬁers have been shown to
work reasonably well, none being inferior to any of the ﬁrst-level classiﬁers. On the
other hand, none of the simple classiﬁers could outperform the ﬁrst-level classiﬁers. In
contrast, the second-level random forest is clearly superior to the single classiﬁers. At
almost every false positive rate, the random forest had a higher true positive rate than
any of the ﬁrst-level classiﬁers (Figure 2.15). The superior performance can be explained
by looking at the prediction landscape of the random forest (Figure 2.16, bottom right).
In strong contrast to the other classiﬁers, the FPR classes are non-uniformly distributed
within the lower left corner. In addition to a rather large landmass there are numerous
islands, interrupted by other FPR-classes. One can ﬁnd two very notable features. One,
a large, rugged island of the 12.5% and 20% FPR classes (orange and green), completely
surrounded by area of low FPR (blue), almost in the center of the landscape. This is
somewhat surprising, because intuitively one might expect that a steady increase of one
of the ﬁrst-level predictions, will result in a steady increase of the second-level outcome.
The opposite phenomenon can be seen in the lower left corner. A lake of low FPR-
class (blue), resulting in an X4 prediction by the second-level model, is found in an area
surrounded by high FPR classes. A similar, smaller lake is located right next to the
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larger one. This surprisingly shaped landscape of the second-level random forest can be
understood when taking a look at the basis of training. Figure 2.14 shows the sequences
located according to the respective ﬁrst-level votes used for training the second-level
model. In essence, the model has learned the shape and locations of the islands, both
blue surrounded by green and orange, and vice versa, because they were present in the
training data. Both areas show a signiﬁcant local amount of sequences of one class, in the
absence of sequences from the other class. Although the training landscape consisted
of the votes of ten ﬁrst-level forests to include the variation in outcomes due to the
randomness during forest generation, it could be that the landscape was not populated
enough to deﬁne a clear uniform shape or general distinction between the R5 and X4
classes. One can argue that due to possibly misclassiﬁed training sequences (X4 in the
lower left corner, R5 in the upper right corner), or coincidental local accumulation of
sequences of one class, the forest was confused, resulting in overﬁtting. The method
of predicting co-receptor tropism based on evaluating independent classiﬁcations on a
second-level has been named T-CUP (Two-level Co-receptor Usage Prediction).
In order to measure the degree to which the second-level random forest was prone to
overﬁtting based on the training data, a blind and independent test set of V3 sequences
was compiled. The set included sequences gathered from literature, as well as two set
of sequences from the Institute of Virology in Cologne and the Computational Biology
group at the Max Planck Institute in Saarbrücken (both in Germany). All sequences
were ﬁltered as described in Material and Methods of this chapter. The ﬁnal validation
set contained 381 sequences in total, with 132 X4 and 249 R5 sequences. First-level
predictions by the electrostatic and hydrophobicity models were performed for each se-
quence. The ﬁrst-level votes were then used as input for the second-level prediction by
the four classiﬁers min, max, product, and the random forest. To complete the perfor-
mance comparison, the test set was also submitted to prediction by geno2pheno[corecpetor]
(http://coreceptor.bioinf.mpi-inf.mpg.de/) using the recommended FPR (12.5%)
and Web-PSSM (http://indra.mullins.microbiol.washington.edu/webpssm/) us-
ing the x4r5 subtype B matrix. The performance of the 11/25 and 11/24/25 rules was
also calculated. The results of the complete performance comparison in form of a ROC
curve, is shown in Figure 2.17. The 11/25, 11/24/25 rules and geno2pheno (g2p) only
gave a binary decision for each sequence, either X4 or R5. For these methods only single
pairs of FPR and TPR could be generated, and are visualized by black dots in the ROC
curve. PSSM calculates a score for each sequence which can be interpreted by a relative
cutoﬀ, thus calculation of a ROC curve was possible (black line). Immediately one no-
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Figure 2.16: Prediction landscapes of the diﬀerent second-level models. The
landscapes show the predictions made by the second-level classiﬁers coded
by colors. The respective ﬁrst-level votes are shown on the axes. While
the simple mathematical classiﬁers (min, max, multiplication) have a
monotonous development from low to high prediction results, the random
forest is not clearly structured, the islands could indicate local overﬁtting.
tices the overall reduced performance of T-CUP on the blind test set. This point will
be addressed in the discussion (Section 2.4). All second-level classiﬁers are performing
equally in the low FPR regions, with about 70% and 75% TPR at the relevant FPR
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or 12.5% and 20%. Astonishingly the random forest, frontrunner in the patientwise
crossvalidation of training data, is even slightly outperformed by every of the simple
classiﬁers. The superior performance of the random forest as second-level classiﬁer on
the crossvalidated training data was thus probably caused by local overﬁtting. The best
performing classiﬁer in the low FPR regions (<20%) seems to be mult. When looking at
higher FPR (beyond 20%) the max classiﬁer stands out. Thus, there is not one superior
classiﬁer, in fact, the right one should is based on the desired FPR. In essence, when
the goal is to include ensure a larger number of eﬀective treatments, the max classiﬁer
seems better suited than any other. On the other hand, when accepting a higher number
of ineﬀective treatments in order to include more patients into therapy with co-receptor
blockers, the more liberal classiﬁers mult or min could be chosen. All T-CUP classiﬁers
performed well in comparison with current state-of-the-art methods geno2pheno and
PSSM, the latter was outperformed by all of them. In direct comparison with g2p, the
mult classiﬁer performed equally well, while the max classiﬁer showed an improvement
of about 5% in TPR at the same FPR of 26%. The 11/25 and 11/24/25 rule based
methods were inferior to PSSM, and all T-CUP classiﬁers.
2.4 Discussion
The results have shown that the combination of more than one prediction model can
improve the prediction of co-receptor tropism based on V3 loop sequences. This has
been shown both for the crossvalidated training data and, more important, on a blind-
validation test set. T-CUP generates independent random forest machine learning mod-
els on a ﬁrst level and combines these using diﬀerent classiﬁers on a second level to reach
a ﬁnal result. Diﬀerent second-level classiﬁers were tested. It has been hypothesized that
a more sophisticated and non-linear second-level classiﬁer, like another random forest,
would outperform more simple second-level models. While this was true for the perfor-
mance based on the crossvalidation of the training data, the random forest did not fare
better than any of the simple classiﬁers during a validation using 381 clinical sequences..
In fact, the random forest, on average, was inferior to any of the simple classiﬁers, min,
max, and mult. There are three possible explanations for this phenomenon. First, the
training data did not contain any sequences originating from Germany, while the se-
quences of the blind test set were exclusively collected in Germany. In that case, the
training data is not a globally representative ensemble of V3 sequences. Second, at least
one of the data sets contained errors. Third, the second-level random forest was overﬁt-
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Figure 2.17: Performance comparison of the diﬀerent genotypic tropism pre-
diction methods. The overall performance is reduced in comparison to
the patientwise crossvalidation on the training data. Still, the two-level
models fare signiﬁcantly better than PSSM and the rule-based approaches.
The random forest second-level classiﬁer is not superior to any of the simple
models. The best models seem to be mult at lower and max at higher FPR.
ted to the training data. In either case, no deﬁnitive conclusion can be made about the
performance of T-CUP. In an attempt to quantify the diﬀerence or similarity between
the initial training data and the sequences in the blind test data set, the training set was
compared to the test sequences. To that end, pairwise alignment scores were calculated
between each pair of training sequences, while limiting the set to a single sequence per
patient (see Section 2.3.1 and Figure 2.9). For each sequence the best score to any of
the other sequences was selected. The distribution of these scores reﬂects how well se-
quences within a set are connected to each other. Then, for each sequence of the blind
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test set, the maximum alignment score to any of the sequences from the training set was
calculated. The distribution of scores is shown in Figure 2.18. The orange curve shows
the distribution of maximum alignment scores of training sequences to other sequences
within the training set. Training sequences seem to be connected rather well with each
other, with most sequences having a high alignment score to at least one other sequence.
Many sequences of the blind test set have a quite considerable distance to the nearest
sequence neighbor in the training set. Obviously the training set used was not a repre-
sentative set for the V3 loop sequence space. It can be assumed, that the performance
for these sequences is signiﬁcantly lower than for sequences with close sequence relation
to the training set.
The improved predictive performance of the models is an important result, but can the
models be used to draw biologically relevant conclusions on the diﬀerence between V3
loops associated with X4 or R5 tropic viruses? The random forest algorithm comprises
a metric by which the relative importance of single model variables can be described,
a so called importance analysis (see Section 2.1.2). In the case of the hydrophobicity
model, each V3 aminoacid sequence was encoded into a numeric sequence, representing
the hydrophobicity of the present residue. Thus, the model learned the tropism, based on
sequences of 38 numerical variables. The importance value calculated for each variable
gives the mean decrease in prediction accuracy, when randomly permuting this variable in
the training sequences. In essence, the higher the importance value, the more important
a variable is for an accurate prediction. Figure 2.19 shows the importance of the 38
variables of the hydrophobicity model, as computed by the random forest algorithm. A
direct interpretation of variables in terms of aminoacid sequence position is impossible,
because the initial hydrophobicity sequences were normalized to a constant length of 38
to cope with the heterogeneity of V3 loop length. Still, the normalized positions closely
reﬂect the initial residue numbering of the V3 loops. The most important variable is at
position 12. This probably coincides with the 11/25 rule, highlighting the importance of
that residue position for distinguishing X4 from R5 sequences. Although the 11/25 and
11/24/25 rules base their prediction on the presence, or absence, of a charged residue at
the respective positions, the hydrophobicity model pays great attention to this position as
well. This can be explained by the hydrophilic nature of charged aminoacids. Charges are
implicitly included in the hydrophobicity scale. Surprisingly, position 25 is not of elevated
importance. The second most important variables for predicting co-receptor usage are
found at positions seven and eight. In the normalized hydrophobicity sequence, these
positions correspond to a region where asparagines are frequently discovered, and are
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Figure 2.18: Sequence similarity of blind test data to training data. Density of
maximum alignment distances of each sequence to other sequences within
in the training data is shown in orange. The distribution of maximum
alignment scores of each sequence of the blind test data set to any sequence
of the training set is shown in blue.
hypothesized to undergo N-linked glycosylation. The post-translational modiﬁcation at
this multi-asparagine motif has been reported to be important for gp120 interaction with
host co-receptors. Ogert et al. [105] found that the mutation of one of the asparagines
at the glycosylation site of the V3 loop into glutamine inhibited the CCR5-mediated
cell fusion, while the same mutation retained about 50% of the wild type fusion activity
with CXCR4. These results were also found in another study, where mutations to the
glycosylation site resulted in a complete reduction of CCR5-usage and only a slight
decrease in CXCR4-usage [81]. Recent ﬁndings have hypothesized that asparagines in
the region are involved in the binding to sulfated tyrosines at the N-terminus of CCR5
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[56]. The importance analysis of the hydrophobicity model supports the relevance of
positions 6-8 (glycosylation) and 11 (11/25 rule) of the V3 loop for co-receptor tropism.
Figure 2.19: Random forest variable importance analysis of the hydrophobicity
model. Importance of positions of normalized V3 sequence in random for-
est classiﬁcation with Kyte-Doolittle descriptor [76]. The higher the peak
at the respective position, the more important this position for correct clas-
siﬁcation of sequences with respect to co-receptor tropism. For orientation,
the HXB2 V3 loop reference sequence is shown above. The most important
region is around normalized sequence position 12, in agreement with the
11/25 rule. The second most important region around position 8 could be
involved in binding of sulfated tyrosine on CCR5 [56].
The importance analysis of the electrostatic model consisted of 642 variables in total.
Each variable represents a value of the discrete electrostatic potential, located on the
electrostatic hull around a V3 loop homology model (see Section 2.1.3). To visualize the
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region of important electrostatic potential, the 5% (n=32) most important variables were
selected. For each of the classes, R5, R5X4, and X4, the mean electrostatic potential
for selected variables was calculated. The results are shown in Figure 2.20, where the
V3 loop is represented as a coil with small beads for the aminoacids (both in gray).
Each loop is surrounded by colored spheres representing the important variables of the
electrostatic hull. The spheres are colored according to the mean electrostatic potential
φ for the respective classes R5, R5X4, and X4. The unit of the electrostatic potential
is kB · 300K/e. The color classes are: red, 〈φ〉 ≤ −2.5; light red, −2.5 < 〈φ〉 ≤
−0.5; white, −0.5 < 〈φ〉 ≤ 0.5; light blue, 0.5 < 〈φ〉 ≤ 2.5; blue, 2.5 < 〈φ〉. The
selected coordinates of descriptive electrostatics are basically divided into three separate
regions. One regions is located around residue 11, in concordance with the 11/25 and
11/24/25 rules, as well as the importance analysis of the hydrophobicity model. However,
in contrast to the hydrophobicity model, the electrostatic model ﬁnds discriminative
information at a second region around position 25. The third region again coincides
with the hydrophobicity importance analysis, as the potential close to residue six is
found to be relevant. At this third region, one can see the advantage of a structural
classiﬁer over a simple sequence-based model. While residues six and 30 are far apart in
primary sequence, they are in close distance in the tertiary structure. The third region,
thus, encloses coordinates right in the middle of the two residues. Interestingly both
have been implicated to interact with sulfated tyrosines of the co-receptor N-terminus
by forming hydrogen bonds [56].
Overall, there are clear diﬀerences in the electrostatic potential at the selected points
between the R5 and X4 classes. The overall mean potential of the R5 loops is more
negative than that of the X4 loops. In fact, on average there is no negative electro-
static potential found in the marked regions of the X4 class. Both ﬁndings are in good
agreement with the electrostatic potential calculated for the extracellular regions of the
co-receptor models. The CCR5 receptor has a strong positive electrostatic potential,
while the CXCR4 model was found to generate a negative potential. These ﬁndings
for CXCR4 have recently been conﬁrmed by calculations on the newly available crystal
structure of the co-receptor [167]. The distribution of φ of dual-tropic V3 loops (R5X4)
is especially interesting. It seems, that the dual-tropic class is a chimera between the R5
and X4 classes. The mean electrostatic potential of the region around residue 11 is highly
positive, resembling the X4 loop, while the potential around residue 25 is more similar
to the R5 class. Around the hypothesized region of N-terminal co-receptor interaction
the potential is weakly positive, resembling neither of the other classes in detail.
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Figure 2.20: Random forest variable importance analysis of the electrostatics
model. 5% most important positions on electrostatics hull for tropism
classiﬁcation by electrostatics based random forest. The backbone of the
template V3 conformation [57] is shown as tube with Cα atoms marked
by small beads and some residues numbered for orientation, starting with
the N-terminal cysteine as residue 1. Important electrostatic features of
the hull are colored according to the mean electrostatic potential 〈φ〉 (unit
kB · 300K/e) in the respective tropism class (red, 〈φ〉 ≤ −2.5; light red,
−2.5 < 〈φ〉 ≤ −0.5; white, −0.5 < 〈φ〉 ≤ 0.5; light blue, 0.5 < 〈φ〉 ≤ 2.5;
blue, 2.5 < 〈φ〉).
The limited number of independent test sequences and the fact that diﬀerent training
data was used for the training of T-CUP, geno2pheno or PSSM make it impossible declare
a front-runner. Future analyses with new sets of V3 sequences will be required to draw a
deﬁnitive result, however, in conclusion, it seems that T-CUP performs at least equally
well, if not better than current state-of-the art methods, like geno2pheno or PSSM.
76
3 Prediction of HIV-1 Co-receptor
Tropism from Quasispecies
The art of science isn't necessarily to avoid mistakes; rather,
progress is often made by making mistakes as fast as possible,
while avoiding making the same mistakes twice.
 Robert Hazen
3.1 Introduction
Soon after the initial infection by HIV-1 the virus evolves by error-prone replication pro-
cesses, evading the immune system, adapting to the host. The result is a diverse swarm
of related, but diﬀering virus variants, the viral quasispecies. Phenotypic tests are able
to detect X4 minority variants, while conventional genotypic tests are limited by relying
on single majority sequences to predict co-receptor usage. Discordance between both
methods is common in a clinical setting. Next-generation sequencing methods are able
to sequence representative subsets of the viral quasispecies, enabling genotypic methods
to make predictions considering minor variants. The two-level co-receptor usage pre-
diction method T-CUP was applied to test concordance between phenotypic results for
twelve samples from a longitudinal phase II vicriviroc study. Moreover, the approach
was found to oﬀer deeper insight into the dynamics of co-receptor usage switching, yield-
ing a possible description of patients with an elevated risk of switching viral co-receptor
tropism.
3.1.1 The Quasispecies
The theory of the quasispecies has ﬁrst been described by Manfred Eigen and Peter
Schuster in the introduction of the hypercycle [35, 36, 37]. It is based on the concept of
low-ﬁdelity replication of RNA in a precellular world as formulated by Manfred Eigen
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in 1971 [34]. The quasispecies is deﬁned as a dynamics distribution of diﬀerent but
closely related replicons [29]. The swarm-like quasispecies is scattered around a master
sequence, which is usually best adapted to the environment. The theoretical quasispecies
extends the classical view of population biology where one constant wild-type sequence
is representative of a population. The wild-type sequence is replaced by a steady-state
ensemble of closely related sequences, with varying ﬁtness. A quasispecies develops
by constant production of novel sequences, through replication errors and selection of
variants. The mutant spectrum describes the composition of the quasispecies. The
mutant spectrum complexity describes the coverage of sequence space and is reciprocal
to the copy ﬁdelity. It thus increases with a decreasing copy quality.
RNA virus population dynamics have been shown to be closely related to theoretical
quasispecies behavior. Sources of erroneous replication in most RNA viruses are the
reverse transcriptase, translating viral RNA into DNA, and the subsequent integration
into the host genome by the integrase. The combined error rate of RNA viruses is
around 10−4 per base and replication cycle. Thus, with a viral genome of around 104
bases, approximately one error is generated in each new virus [17]. In addition to the
intrinsic error source of viral replication, recombination events can take place in the case
of infection of a host cell my multiple virus variants. Driven by the constant pressure
induced by changing environmental factors, such as the host immune system, a diverse
viral quasispecies can quickly emerge. The error rates of RNA viruses are close to the
threshold of a so-called error catastrophe. With a rising error rate, the frequency of
the master sequence decreases until the rate reaches a threshold of around 10−3, at
which point the mutant spectrum becomes so diverse, that the conservation of single
variants is very unlikely. This insight has been exploited to successfully eradicate viral
populations by raising the error rate to critical levels through mutagenic nucleosides [97].
It has been proposed that viral quasispecies have a memory, in form of minority variants,
for genomes that once dominated the populations [122]. In vivo, this is facilitated by
an archive of integrated provirus reservoirs, unaﬀected by antiretroviral therapy [12].
Indeed, the reemergence of variants that have been successfully controlled by ART can
be witnessed, once the drug is omitted [63, 8].
3.1.2 Next-Generation Sequencing
For decades, the automated Sanger sequencing was the standard method for determining
DNA sequences. It is based on the original sequencing method by random chain termi-
nation events proposed by Frederick Sanger [127, 128] (Figure 3.1). To determine the
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sequence of a single stranded DNA, the template is distributed into four tubes, together
with a DNA primer, DNA polymerase and ﬂuorescently labeled dNTPs (dA, dG, dC,
dT). Finally, ddNTPs, necessary for chain termination, are added, one type (ddA, ddG,
ddC, ddT) for each tube. The ddNTPs are dNTPs, lacking the 3'-OH-group, required for
bond formation with the subsequent nucleotide. During the elongation reactions in each
tube ddNTPs will randomly be used, terminating the chain. Thus, a more or less equal
distribution of resulting chain lengths can be expected. By means of gel-electrophoresis,
the chain fragments of each tube can be separated by size, one lane for each tube.
Figure 3.1: Sanger sequencing. Illustrations taken from Cooper and Hausmann [20].
The automated Sanger sequencing applies ﬂuorescent dyes at the ddNTPs, one color
for each type of ddNTP, reducing the number of parallel reactions required [141, 140].
Instead of four parallel reactions chain fragment are generated in a single reaction. The
type of ddNTP terminating the fragments can be visualized in an automated manner.
Sanger sequencing has been a key to many discoveries and scientiﬁc breakthroughs such
as the ﬁrst sequencing of the complete human genome [64]. However, a major limitation
of the method lies in the length of sequences that can be determined. Clear separation of
fragments after approximately 700 bases is diﬃcult and results in decreasing signal qual-
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ity. For the determination of whole-genome sequences this means splitting the genome
DNA into small fragments, using each as a template for sequencing. This approach is
referred to as shot-gun sequencing. A tedious and expensive task using Sanger sequenc-
ing.
The Sanger method was regarded as a 'ﬁrst-generation-sequencing' technology [94].
Recently the emphasis has shifted towards automated, highly parallel sequencing meth-
ods, able to determine sequence of large genomes in less time and at lower price. Next-
generation sequencing (NGS), technologies combine methods of sequence template prepa-
ration, sequencing and subsequent data analysis. The aim is the automated, cost-eﬃcient
generation of huge amounts of sequence data, to be used for whole-genome sequencing,
transcriptome and sequence variation analysis. Already, NGS has made a huge impact
on various ﬁelds of biology, especially on the ﬁeld of whole-genome sequencing. The
sequencing of J. Craig Venters personal genome by automated Sanger cost around 70
million US dollars. Sequencing of the genome of James D. Watson by Roche/454 cost
a comparably small amount of one million US dollars. Other genomes have been de-
termined by as little as 250.000 to 48.000 US dollars [94]. A handful of technologies
are currently commercially available: GS FLX Titanium by Roche/454, SOLiD 3 by
Life/APG, and the Genome Analyzer II by Illumina/Solexa. The technologies all rely
on the generation of many short DNA fragments, so called reads. They diﬀer in aspects
such as the number or length of reads produced, run-time, or error-rate. The methods of
how reads are generated and sequences are determined also varies between the diﬀerent
platforms. In this work, sequences generated by Roche/454 have been used and, thus,
only the methods of this particular technology will be discussed here.
The sequencing technology initially developed by 454 Life Sciences [91] consists of
three phases: preparation of template sequences, sequencing and imaging, evaluation
of imaging data. A schematic overview is shown in Figure 3.2. Thousands of DNA
fragments can be sequenced in parallel. The source of DNA fragments to be sequenced
depends on the experiment. For whole-genome sequencing the genomic DNA is randomly
sheared into single DNA fragments. In the case of variant analysis, where the variability
of one or more genomic regions is to be determined, regions of interest are extracted by
speciﬁc primers targeting the ﬂanking regions. The extracted DNA regions can then be
used for sequencing and ampliﬁcation. Central to sequencing process is pyrosequencing.
Pyrosequencing is a bioluminescence method, measuring light that is emitted during
each extension step. The amount of light emitted is very small, and thus, it is necessary
to produce many extension events occurring at once. This is ensured by amplifying the
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DNA fragments to be sequenced by emulsion PCR (emPCR) [31]. For this, adapter
sequences containing universal primer sites for ampliﬁcation and sequencing, are ligated
to the ends of the single stranded templates. Via these adapters the templates bind
to beads under conditions favoring one template per bead. Following the attachment
of templates, each bead is captured within a water droplet in an oil phase, so called
microreactors, additionally containing primers, dNTP, and DNA polymerase. In these
microreactors, parallel DNA ampliﬁcation is performed, producing around 107 copies
of the template attached to a single bead. After successful ampliﬁcation, the emulsion
is broken and the beads placed within small wells along a ﬁbre optic glass slide, a
PicoTiterPlate (PTP). The well radius restricts the occupation of beads to one per well.
The preparation process is illustrated in Figure 3.2A. The beads placed in the wells,
covered with millions of identical DNA templates are now subjected to pyrosequencing.
For pyrosequencing, a large number of considerably smaller beads, covered with luciferase
and sulphurylase as well as polymerase are added to the wells. In an iterative process
dNTPs of the same type are now added to the wells. Upon incorporation, a light is
emitted and recorded by a CCD camera, attached beneath the ﬁbre-optic slide (Figure
3.2B). The high resolution camera is able to speciﬁcally record signals for each well. The
signals of each well are translated in a ﬂowgram (Figure 3.2C). This ﬂowgram signal
is then normalized to remove background noise. The x-axis shows the nucleotides that
were incorporated, based on the color of the light emitted. The number of times each
nucleotide was subsequently incorporated during dNTP ﬂow can be read from the signal
intensity, shown on the y-axis.
3.1.3 Tropism Prediction and the Viral Quasispecies
Over the years, several groups have reported lacking accuracy of genotypic tropism pre-
diction methods in a clinical setting [87, 139, 88, 129], or rather an unsatisfying rate of
discordance between the results of genotypic and phenotypic methods. This phenomenon
can readily be explained by the viral quasispecies. By means of NGS methods, groups
have described the existence of hundreds of unique virus variants within single patients
[151, 121, 1]. While tropism prediction is usually performed on a single sequence de-
rived from the patient by ampliﬁcation and determination of the most prominent virus
variant in a patients quasispecies, phenotypic methods, such as Troﬁle, will consider
the whole quasispecies. For the same patient genotypic and phenotypic methods can
produce discordant results if the most prominent variant is indeed an R5 virus, but the
mutant spectrum includes X4 variants in suﬃcient concentration to be picked up by
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Figure 3.2: Parallel sequencing method of Roche/454 GS FLX Titanium. Illus-
trations taken from Metzker 2010 [94].
the phenotypic assay. A straightforward strategy to improve detection rate of minority
strains is to perform multiple sequencing rounds. Triplicate sequencing oﬀers an im-
proved detection rate but increases laboratory work and sequencing costs. This strategy
succeeded in improving the concordance of genotypic and phenotypic methods [145]. In
the same study, the authors reported that independent triplicate ampliﬁcation from the
same sample produced diﬀering sequences and tropism prediction results in 19% of the
cases. This especially applied to sequences classiﬁed as X4 by the Troﬁle test. In that
case, almost half of the samples yielded at least one sequence that was classiﬁed as R5
by the phenotypic test. The overall sensitivity could be improved by nearly 20%.
Triplicate sequencing improves the prediction accuracy of genotypic test by an in-
creased detection rate of minor variants. Next-generation sequencing methods oﬀer an
even more robust and reliable way to pick up minor virus variants from patient samples
by so-called ultra-deep sequencing (UDS). UDS allows the detection of mutations ex-
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pressed at very low levels, by sequencing many variants of speciﬁc fragments of DNA or
RNA found in samples. In 2010 Vandenbroucke et al. [156] have proposed a genotypic
tropism prediction scheme based on UDS data acquired from patients failing phenotypic
tests. Phenotypic tests have been known to fail, i.e. being unable to produce any re-
sults, in more than 15% of the cases [114], often caused by low viral load. The authors
proposed to sequence the V3 loop region of the patients viral quasispecies to be used for
genotypic prediction. To exclude ghost variants, caused by infrequent sequencing errors,
they only considered variants with a frequency of more than 1% of the sequences. For
their prediction, the authors used geno2pheno [136] and PSSM [65] via the respective
web services. In total, 14 samples were sequenced and predicted, ﬁnding concordance
with the phenotypic results in 12 of the cases. In a similar study, Swenson et al. analyzed
the potential of UDS data gathered by 454 sequencing and found concordance with phe-
notypic tests in all twelve samples [145]. A year earlier, Tsibris et al. had sequenced the
V3 loop area of the quasispecies of four patients under treatment with the co-receptor
antagonist vicriviroc [151]. They focused on the analysis of the quasispecies composition
without performing extensive genotypic tropism analysis. Using ultra-deep sequencing,
they found experimental evidence that minor variants responsible for co-receptor switch-
ing were not generated de novo during one replication cycle, but had already existed at
treatment start. Furthermore, they could highlight the clinical relevance of minority
variants present at frequencies of less than 1%, a concentration at which these variants
were not detected by the standard Troﬁle assay. The standard Troﬁle assay was able to
detect X4 viruses down to a concentration of 5-10% [160] and has recently been replaced
by the Enhanced Sensitivity Troﬁle Assay (ESTA), detecting X4 viruses at concentra-
tions as low as 0.3% [149]. The two-level tropism prediction method described in chapter
2, was shown to perform better than standard current state-of-the-art methods on an
independent testset, consisting of clinical samples containing discordant calls by pheno-
typic and genotypic tests. In order to test the accuracy of our method when evaluating
not a single sequence but a set of sequences, representative for the whole viral quasis-
pecies of a patient, we applied it to the sequence data deposited by Tsibris et al. This
longitudinal study, provides an insight into the evolution of the viral quasispecies under
drug pressure. The authors examined four patients during the course of treatment with
the co-receptor antagonist vicriviroc (VVC). All patients were enrolled in a phase II
clinical trial of VVC. In the initial clinical trial, phenotypic testing of patient tropism
was performed at various times. These patients were chosen speciﬁcally, because they
had a common feature: they all developed virologic failure, deﬁned as failing to achieve
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and maintain a reduction by >1 log10 of viral load at or after week 16. For each of the
patients, the authors determined the viral quasispecies by 454 ultra-deep sequencing, at
three distinct times. The ﬁrst sequencing was performed prior at treatment start (week
0) to establish a baseline. The second and third times of sequencing were chosen inde-
pendently for each patient, based on the ﬁrst ﬁnding of CXCR4 viruses by phenotypic
testing and ﬁnally when virologic failure occurred. In case CXCR4 viruses could not
be detected prior to virologic failure, the next point of available plasma was used for
sequencing. To us, this study presented the opportunity of evaluating the performance
of our method when using ensembles of V3 variants, also including minority variants,
rather than using single sequences based on population majorities.
3.2 Materials and Methods
V3 Deep Sequencing Data V3 deep sequencing data was publicly available from
the NCBI Short Read Archive (accession numbers SRS000811-SRS000829), were it was
kindly deposited by Tsibris et al. [151]. The source of this longitudinal data were
four patients under vicriviroc treatment. The V3 region of each patients quasispecies
was sequenced on three occasions, resulting in twelve unique quasispecies compositions.
Sequencing was done using the 454 GS FLX sequencing platform by Roche (Roche, Palo
Alto, CA). Detailed information on primer design, preparation and further technical
detail can be found in the original publication. To extract the V3 sequences from each
sample, reads were aligned in forward and reverse manner against the reference HXB2-
V3 strain by Smith-Waterman local alignment [142]. Reads shorter than 105 nucleotides
were not considered. The resulting sequences were then translated into aminoacid code
and grouped by sequence, counting the number of occurrences.
Read Frequency Cutoﬀ In order to estimate the error rate of the PCR ampliﬁcation
carried out during deep sequencing, Tsibris et al. performed validation runs using an
artiﬁcial quasispecies. This ensemble consisted of three unique clones from of the patients
with frequencies of 0.89, 0.1, and 0.01. They report that this ratio was essentially
preserved after ampliﬁcation and post-processing. However, 4.5% of the newly ampliﬁed
variants showed mutations with regards to the input sequences. The vast majority
of errors were single-nucleotide mutations (99.8%). The per-nucleotide error-rate was
estimated to be 0.0011 and 0.0016 in two independent experiments. This error-rate
results from a combination of ampliﬁcation and the applied deep sequencing protocol,
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after ﬁltering of problematic sequences. We use this error-rate estimation to determine
a cutoﬀ for ﬁltering out minority variants that might have emerged due to experimental
errors, rather than as consequence genomic variation. The question we raise is: what is
the minimal amount of identical sequences that has to be present in order to accept this
variant as a true variant? This was answered by using binomial probabilities.
If mutations are assumed to occur independently and with the same probability p
along the sequence, the probability of having exactly k errors on a nucleotide sequence
of a given length n can be calculated as a binomial probability:
P (n, k) =
(
n
k
)
pk(1− p)n−k
Using a mean V3 nucleotide sequence length of 105 bases and the per-nucleotide error-
rate of 0.0016 we calculate the probability of having exactly one error by
P (105, 1) ≈ 0.14
In turn, the probability of encountering the same error in a second sequence, originat-
ing form the same source sequence, can be calculated by
p = P (n,k)
2
n
= P (105,1)
2
105
≈ 0.0002
Note that this is a conservative estimate since diﬀerent nucleotides are not considered.
The calculation can be extended to estimate the probability of ﬁnding the same error in
m sequences, originating from the same source by
p = P (n,k)
m
nm−1
An erroneous sequence can have more than a single mutation, thus the probability is
expressed as the sum of the probabilities of all possible parallel mutations (n = 105):
p =
n∑
k=1
P (n, k)m
nm−1
We calculated the probabilities of diﬀerent variant frequencies m = {1, ..., 5} to occur
by chance. These probabilities multiplied by the maximum amount of reads produced
by a single deep sequencing experiment (c) gives number of false-positives (variants
resulting from sequencing error that are being accepted) to be expected per experiment.
The results are visualized in Figure 3.3. Choosing a cutoﬀ of at least four observations
of a variant in order to be accepted as a true variants seems a reasonable choice, as it is
estimated to produce less than one false positive in one of 104 UDS experiments, each
generating 105 reads. In the rare case where a false positive is produced, it is likely to
be an infrequent variant with very little impact on the overall quasispecies structure.
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Figure 3.3: Expected number of falsely sequenced variants per quasispecies.
The number of falsely accepted variants, resulting from sequencing error per
UDS experiment decreases exponentially with an linearly increasing variant
cutoﬀ. Choosing a cutoﬀ of at least four variants results in less than one
falsely accepted variant in around 104 UDS experiments, each producing 105
reads.
Distance Calculation A prediction in the two-dimensional prediction plane consist
of two elements: the single predictions made by the electrostatic and hydrophobicity
models. It is of the form
p =
(
p(ESP )
p(hydro)
)
Distances between predictions in the prediction plane are treated as Euclidean distances,
calculated by
dprediction(p1, p2) =
√
(p1p(ESP ) − p2p(ESP ))2 + (p1p(hydro) − p2p(hydro))2
Alignment distance calculations are based on pairwise local alignment using the Smith-
Waterman algorithm [142] and the BLOSUM62 matrix. Alignment distances represent
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a sequence similarity score normalized between 0 and 1 by
dalignment(s1, s2) = 1− A(s1, s2)
A(s1, s1)
. The minimum alignment distance of zero is achieved by aligning a sequence to itself.
Co-receptor Usage Prediction Prediction of co-receptor usage of V3 sequences was
performed using T-CUP as described in Chapter 2, applying the random forest second-
level classiﬁer. The cutoﬀ between X4 and R5 classes was set to 0.02.
3.3 Results
3.3.1 Prediction of Tropism Based on the Viral Quasispecies
After downloading the sets of reads, we extracted probable V3 sequences and discarded
variants with a frequency of less than four reads per sample. Filtering scheme and read
cutoﬀ have been described in detail in the Materials and Methods section. For every of
the twelve sets we predicted the tropism of each unique sequence present. The number
of unique sequences analyzed from each sample is shown in Table 3.1. For each sample
we ﬁrst calculated the number of sequences predicted as X4, relative to the complete
sequence ensemble. For each patient we thus received three values, which could be used
to draw a trend of X4 population development over the course of treatment. These
fractions were then related to the X4 fraction of the viral load, which was taken from
the original publication by Tsibris et al. The progressions of the X4 fraction of the
quasispecies and the X4 fraction of the viral load are shown in Figure 3.4. Overall, we
were able to reproduce the results of Troﬁle testing in all of the cases where sequence
data of the viral quasispecies was available together with a Troﬁle result. This was the
case in 75% of the samples. In the remaining three cases, we extrapolated linear trends of
the X4 fraction progression, which were in complete agreement with Troﬁle results prior
and/or after the times of sampling. Interestingly, we could reproduce the X4 detection
level of the standard Troﬁle assay, which detects X4 viruses at fractions of 0.1 of the
total population [160]. This level was reproduced in all nine cases, when a Troﬁle result
was provided with the quasispecies sequences.
At therapy start, all four patients were conﬁrmed negative for majorities of X4 viruses
(week 0) by the standard Troﬁle assay. We predicted a fraction of 60.01 of X4 viruses
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Table 3.1: Unique V3 sequences extracted from quasispecies samples. Number
of unique sequences used in the analysis for each patient and each of the
three sample times. Based on the data provided by Tsibris et al., a cutoﬀ
of a minimum of four reads per sequence was applied to limit the number of
spurious sequences.
Patient time 1 time 2 time 3
07 174 112 86
18 240 112 41
19 148 134 104
47 126 84 78
in each of the patient samples. From there, patient quasispecies diverged. Subject 07
does not develop a detectable X4 population until week 19, according to Troﬁle. A close
examination of the quasispecies sequenced at weeks 12 and 19, reveals an increasing frac-
tion of X4 viruses, of 0.097 and 0.76, respectively. It is noteworthy that Troﬁle missed to
capture the X4 population at week 12. The upward trend, however, is clearly visible by
genotypic prediction considering the quasispecies. Subject 18 quickly developed a major
X4 population with more than 99% of viruses being predicted as X4. This high level of
X4 viruses is maintained until the last time of sequencing at week 16, and X4 tropism is
conﬁrmed by Troﬁle testing at weeks 8, 12, 20, and 23. The development of Subject 19
is particularly interesting. Phenotypic testing detects X4 viruses at weeks 2 and 10 but
not at week 22. The predicted X4 fractions for samples at weeks 2 and 17 indeed repro-
duce this trend at 0.49 and 0.12, respectively. Unfortunately, no sequencing has been
performed at week 23, but a linear extrapolation of the X4 fraction progression, predicts
the population of X4 viruses to fall below Troﬁle detection threshold of 0.1. According
to Tsibris et al. this patient had a poor adherence prior to experiencing virologic failure.
Subject 47 never developed any strong X4 population, neither Troﬁle nor the genotypic
testing performed on our side revealed any major X4 strains. According to the authors,
the reason for this development remains unclear, however a failing antiretroviral regimen
is possible, even though a loss of VVC susceptibility could not be demonstrated.
The analyses so far have shown that results by standard Troﬁle testing can be repro-
duced by genotypic prediction of quantitative deep sequencing data. In fact, the case of
subject 07 hinted that this method is even superior to standard Troﬁle in terms of detec-
tion of minor X4 populations. To further evaluate the potential and relevance of UDS in
clinical practice, we performed more detailed analyses of the quasispecies structure. In a
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Figure 3.4: Development of predicted fraction of X4-using viruses in four
patients during vicriviroc treatment. Labels R5(R5-using) and
DM(dual/mixed or X4-using) are Troﬁle predictions of the patients' qua-
sispecies. Predicted relative X4 fraction from patient samples are marked as
orange squares and annotated by the right axis. The gray areas show the
calculated viral load, based on the predicted X4 fraction and viral loads pub-
lished by the Tsibris et al [151]. The dotted lines mark the 10% detection
rate of standard Troﬁle assay.
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ﬁrst step, we took a closer look at patients developing a co-receptor switch and a major
X4 population. Tsibris et al. had already reported that patients 07, 18, and 19 carried
minor X4 variants at baseline (week 0), which later developed into major populations.
The authors used the publicly available PSSM tool to predict co-receptor tropism from
sequences. Using our prediction method, described in chapter 2, we were able to conﬁrm
these ﬁndings. Table 3.2 shows the progression of the single most prominent X4 variants
of patients identiﬁed at week 0. All of these variants, with the exception of subject
47, develop into dominating variants under drug pressure, despite initially representing
only fractions of 0.005 to 0.01 of the quasispecies. In subject 07 the most prominent
variant alone accounted for a considerable viral load of over 6000 copies/mL. In subjects
18 and 19, the most often occurring X4 variant was not represented as frequently as
that found in subject 07, which is even more alarming, considering their proliferation
under drug pressure. The most frequent X4 variant at week 0 of subject 07 accounts
for only a fraction 0.0009 of the total population, the viral load of that variant consists
of around 100 copies/mL. In fact, it has completely vanished by week 17. The most
frequent baseline X4 variants of subjects 18 and 19 are present at around 300 and 900
copies/mL. Figure 3.5 shows the correlation of baseline X4 variants and the overall X4
population. The progressions of the most frequent baseline X4 variant and the overall
X4 population are highly correlated. Pearson correlation testing, omitting subject 47
due to vanishing of the variant, yields a correlation of R2 = 0.975 with p = 6.7 · 10−7 for
the null hypothesis of zero correlation. The close to linear correlation depicted by the
dashed line in Figure 3.5 shows that minor baseline X4 variants are responsible for the
long-term overall population development.
Table 3.2: Development of most prominent baseline X4 virus strains. Develop-
ment of the X4 seed strains in subjects 07, 18, 19 with tropism switches and
the largest initial X4 strain in patient 47 who does not show a tropism switch.
The three times are the sampling points along the Time axis in Figure 3.4.
Patient Variant Fraction of population at
time 1 time 2 time 3
07 CTRPGNNTRRSIRIGPGQTFFAREDIIGDIRQAYC 0.01 0.07 0.73
18 CERPNNNTRQRLSIGPGRSFYTSRRIIGDVKKAHC 0.005 0.79 0.71
19 CTRPNNNTRKGIYLGPGRAFYTTDKIIGDIRQAHC 0.007 0.43 0.08
47 CTRPNNSTRKSINIGPGSAWYTTGDIIGDIRQAHC 0.0009 0.0 0.0
90
3.3. Results
3
−5 −4 −3 −2 −1 0
−
5
−
4
−
3
−
2
−
1
0
Fraction all X4 [log]
Fr
a
ct
io
n 
X4
 s
ee
d 
[lo
g]
l
l
l
l
l
l
Subject 07
Subject 18
Subject 19
l Time 1
Time 2
Time 3
Figure 3.5: Correlation of most prominent baseline X4 strain and total X4
population. The fraction of the most prominent baseline X4 strain against
the total X4 fraction is shown for all patients (coded by color) developing a
tropism switch and time points (coded by symbols).
3.3.2 Structure of Viral Quasispecies as Indicator for Tropism
Switches
T-CUP relies on two voting results made by independent models (see Section 2.3.3). The
two outcomes are then combined by a second-level model to reach a ﬁnal decision. In the
above analyses, V3 sequences were classiﬁed by the ﬁnal classiﬁcation of this two-level
approach. The occasional discordance between the independent ﬁrst-level outcomes were
discussed and introduced as justiﬁcation for the second-level model. Figure 2.14 visual-
izes this phenomenon. In these prediction planes, V3 sequences are located according
to the numerical outcome of the independent ﬁrst-level outcomes. These represent a
pseudo-probability of being an X4 virus. Thus, sequences with a clear X4 prediction by
both models, hydrophobicity and electrostatic potential, are located in the upper right
quadrant of the prediction plane. In the lower left corner, one ﬁnds sequences, with a
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concordant R5 prediction. The two remaining quadrants contain sequences where the
two ﬁrst-level models disagree. The quadrants result from an arbitrarily chosen cutoﬀ
below which sequences are interpreted as R5 variants. Using the cutoﬀs chosen here,
each model had a speciﬁcity of 90%, or false positive rate of 0.1, correctly classifying
90% of the R5 sequences during crossvalidation of the training data.
Here, we analyzed the patients quasispecies structure by positioning each unique se-
quence of a patient into the prediction plane. Figure 3.6 (page 93) shows the prediction
planes containing the quasispecies at subsequent time points (left to right) of patients 07,
18, 19, and 47 (top to bottom). The number of occurrences of each sequence is encoded
by a color key. Sequences with more than 3, 10, 100, or 1000 occurrences are represented
as dots, colored in red, orange, yellow, and white, respectively. The most frequent base-
line X4 variants are marked by green arrows. At week 0 sequences of all patients are still
largely clustered in the lower left corner, visualizing the predominance of R5 variants.
Over the course of treatment, the quasispecies of subject 07 detaches from the R5 corner
and slightly moves towards the cutoﬀs of the ﬁrst-level predictions. One can witness the
R5 population dividing into two distinct clusters, starting at week 12. This process is
accompanied by a thinning-out of the initial R5 population directly attached to the lower
left corner. By week 19, the newly developed cluster is clearly visible, while the initial
R5 population has largely disappeared. Although many variants are located within the
R5 quadrant, deﬁned by the ﬁrst-level predictions, the second-level model classiﬁes most
of these as X4 variants due to its relatively conservative cutoﬀ of 0.05. At this strict
cutoﬀ level, the model tends to classify variants without a clear R5 vote from both the
hydrophobicity and electrostatic potential models as X4 variants. The quasispecies pro-
gression of subject 18 is much clearer. The X4 population, already visible at week 0 in
the upper right corner, grows rapidly within the ﬁrst two weeks of treatment, while the
R5 population quickly disappears. By week 16, the population consists of X4 viruses
almost exclusively. Subject 19 clearly develops a major X4 population by week 2. Like
in subject 07, this process is accompanied by the development of a separate X4 cluster.
This quasispecies nicely demonstrates a reciprocal correlation between R5 and X4 pop-
ulations. While the R5 population decreases at week 2, the X4 population increases. At
week 17 this development is reversed, with a shrinking X4 population and a reemerging
R5 population. This quasispecies actually undergoes two co-receptor switches within 20
weeks. Subject 47 never shows any substantially populated clear X4 variants.
The prediction planes helped in visualizing the clustering process of X4 and R5 popu-
lations during co-receptor switches and the reciprocal correlation between the two pop-
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Figure 3.6: Quasispecies development of patients over time. Virus population de-
velopment of patients (top to bottom) over time (left to right). The axes show
independent predictions of the ﬁrst level of T-CUP, based on electrostatic po-
tential and hydrophobicity. Dashed lines represent cutoﬀ levels between R5
and X4 classes. Cutoﬀs were chosen at 90% speciﬁcity in the training set.
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ulations. The clustering process was observed in all of the cases where a co-receptor
switch occurred. In fact, it might serve as an early indicator for a switch occurring in
the near future. While at week 0 the quasispecies are still dominated by R5 viruses,
baseline X4 variants responsible for co-receptor switches in patients 07, 18, and 19 are
already visible and can be clearly distinguished from other minor variants (Figure 3.6,
green arrows). Speciﬁcally, these variants share two important features: ﬁrst, the have
reached a critical number, as the color code clearly distinguished them from other minor-
ity variants; second, because of their number, these variants are serving as seed for new
variants by producing oﬀspring. Looking at the quasispecies in the prediction planes,
one can see distinct variants close to the X4 seed variants. This can be seen for all three
dominating baseline X4 variants of patients 07, 18 and 19. The assumption that a close
distance on the prediction plane can be interpreted as a close sequence relation, how-
ever is not directly clear. In order to test this assumption, we correlated the Euclidean
distance of variants in the prediction plane to the actual sequence distance. Speciﬁ-
cally, for every quasispecies we calculated the distances of all variants to the X4 seed
variant of the respective patient, referred to as prediction distance. In addition, for
every resulting pair we calculated a sequence distance measure, referred to as alignment
distance (see Materials and Methods of this chapter). The correlation of prediction
distance and alignment distance for each patient and quasispecies is shown in Figure
3.7. R5 variants are shown as blue dots, X4 variants in orange. Patient 47 was excluded
from the analysis, as no co-receptor switch had occurred. In each of the quasispecies
plots, the seed variant, to which all other variants are compared, is found in the lower
left corner. Its prediction and alignment distance to itself is obviously 0. At treatment
start, the X4 population of subject 07 shares a close sequence similarity to the seed
strain, the R5 population is more spread out with higher sequence distances on average.
In the prediction plane, however the X4 population is more distant to the seed strain,
than the R5 population. This can be understood when looking at the prediction plane
and the location of the seed strain (green arrow). The seed is located very close to
the cutoﬀs. A higher cutoﬀ would have predicted this variant to be an R5 virus. The
situation does not change at week 12, except for a marginal decline of X4 diversity. The
relative fraction of X4 viruses was predicted to be just under 10% at that time. By week
19, the X4 population accounted for over 70% of the population. Accordingly, it was
more closely located to the seed strain, hypothesized to be responsible for the overall
X4 progression. Both, prediction and alignment distances of the overall X4 population
to the seed variant have decreased during the course of treatment. Unfortunately, due
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to the close vicinity of the seed strain to the R5 quadrant in the prediction plane and
the overall population sequence similarity, a relation between closely related oﬀspring
and the outcome of prediction could not be established. The proposed relation could,
however, be shown in subjects 18 and 19. The X4 population of subject 18 was relatively
diverse at treatment start, with variants reaching alignment distances from close to zero
up to over 0.6, compared to the seed X4 strain. In comparison, the R5 population is
clearly separated from the seed strain, showing that the V3 loop of the seed already has a
considerable genetic distance to the initial R5 population. Looking at the prediction dis-
tance, a correlation with sequence distance can be seen for the X4 population. Through
weeks 2 and 16 the X4 population increases and later shares a close relation in sequence
and prediction outcome to the proposed seed strain. The genetic diversity of subject
19 is not as great as that of subject 18, showing smaller extreme alignment distances.
As in subject 07 the overall X4 population is closely related to the R5 population when
looking at sequence distances. In the prediction plane, the X4 population is composed
of three clusters, which become apparent when calculating the distances from the X4
seed variant. Some variants are closely coupled to the seed strain in both alignment and
prediction distance, while another group overlaps with the R5 population. An outlying
third group has quite a considerable prediction distance. The prediction plane of subject
19 at week 0 tells us that this outlier group consist of a small number of X4 variants
with a clear X4 prediction, while the seed variant is located nearer, but clearly outside
the R5 quadrant. While the composition and position of the R5 population remains un-
changed throughout treatment, the ﬁrst cluster around the seed strain grows in number
of variants, reaching a peak at week 2, then decreasing again by week 17. Generally, one
can see in this patient that a close distance to the seed strain in then prediction plane
also means a close genetic relation.
3.4 Discussion
The high prediction accuracy of genotypic prediction methods based on UDS data cou-
pled with the ability to detect X4 minority variants are encouraging. However, the rather
limited amount of samples makes further in-depth analyses necessary. The use of UDS
for the clinical practice is dependent on its cost-eﬃciency. Currently, a single 454 run
costs in the order of 10.000 dollars and takes a few days, considering preliminary prepa-
rations, post-processing of reads, and genotypic testing. In comparison, phenotypic tests
like the Troﬁle assay cost around 1500 USD and takes at least two weeks. The availabil-
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Figure 3.7: Alignment distance vs. prediction distance. The plots show the pre-
diction and alignment distances of each sequence of the quasispecies to the
X4 seed strain. The prediction distance is calculated as Euclidean distance
between the points in the prediction plane (see Figure 3.6 on page 93). The
alignment distance is calculated as described in the Materials and Methods
section of this chapter.
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ity of NGS technologies, required to perform ultra-deep sequencing, is still limited. Due
to the broad experimental spectrum of the technology, however, a development towards
a more broad availability is to be expected. The higher costs of UDS experiments, com-
pared to phenotypic testing, does not necessarily have to limit the use of UDS in clinical
practice. Most NGS technologies allow the parallel analysis of samples. Thus, samples
from more than one patient can be sequenced at a time, resulting in less reads generated
per sample. The genotypic prediction is then based on less reads, possibly missing minor
variants and reducing the overall accuracy. To test the performance of our method based
on the read coverage, we simulated sequencing runs by random sampling of reads from a
quasispecies. In detail, sequencing of each of the twelve quasispecies was simulated the
process by random sampling with replacement of reads, calculating the relative fraction
of X4 viruses based on the sample. For each quasispecies the experiment was repeated,
steadily increasing the number of randomly chosen reads by 1000, starting at 100 in the
ﬁrst round. For each sample size, the experiment was repeated 200 times, to calculate
95% conﬁdence intervals for the relative X4 fraction derived from the sample of size n.
The results are shown in Figure 3.8. As expected, the relative fraction of X4 viruses,
calculated from the randomly chosen samples, converges with a growing sample size. It
is, however, surprising how fast this convergence occurs. Our results suggest, that read
coverages as low as 10.000 reads per sample, are suﬃcient to sample a representative
subset of the viral quasispecies. In the case of 454 sequencing technology, the state of
the art machine, the GS FLX Titanium Series, is able to produce around 1 million reads
per run, while the more aﬀordable GS Junior produces on the order of 100.000 reads per
run. Even in the latter case, this would translate to a parallel sequencing of ten patient
samples, reducing the cost per patient to around 1000 US dollars. It is to be expected
that read coverages will be further increased in the future, reducing the cost per reads
or patient.
97
3.4. Discussion
3
Figure 3.8: Population reconstruction with varying read coverage Quasispecies
were resampled using an increasing amount of reads. The relative fraction of
X4 viruses was then calculated from the generated samples. Results quickly
converge to the predicted X4 fraction using all sequences, shown by the or-
ange line.
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4 Summary and Outlook
You gotta have fun. Regardless of how you look at it, we're
playing a game. It's a business, it's our job, but I don't think
you can do well unless you're having fun.
 Derek Jeter
4.1 Summary
In this work, a new method to predict the HIV co-receptor tropism from HIV genotype
was developed. The method comprises a two-level random forest machine learning ap-
proach, generating two independent predictions based on the electrostatic potential and
the hydrophobicity of the V3 loop of HIV envelope protein gp120. The ﬁnal prediction
is reached by combining the ﬁrst-level votes. This was done using diﬀerent combina-
tion methods: the simple mathematical functions min and max, multiplication, and
training of an additional random forest model. First results showed superiority of the
random forest over other methods, but a blind test set of clinical V3 loop sequences
with known co-receptor tropism suggested otherwise. In a closer analysis, generated
prediction landscapes showed indications of an overﬁtting eﬀect by the second-level ran-
dom forest, explaining its non-superiority over the other methods for the clinical test
set. Still, the two-level approach showed an improvement over single prediction models
ESP and hydrophobicity. However, prediction accuracy was not perfect. This eﬀect of
discording assay-determined phenotype and genotypic prediction could be explained by
heterogeneous viral quasispecies, where minority X4 virus populations might be detected
by phenotypic tests, while standard sequencing produces the V3 loop sequence of the
majority R5 virus. To investigate this point, quantitative deep sequencing data sets,
containing representative cross-sections of viral quasispecies were analyzed. These sets,
produced by Tsibris et al. [151], resulted from a phase II clinical trial of patients receiv-
ing vicriviroc, a small molecule co-receptor antagonist. Plasma samples of four patients
experiencing virologic failure were selected for ultra-deep sequencing at treatment start,
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after showing assay-detectable X4 viruses and ﬁnally after virologic failure. In this work,
co-receptor usage of all V3 loop sequences of each quasispecies was predicted. A perfect
concordance was found between the fraction of sequences predicted as X4 and phenotypic
results, applying the detection level of the test used. Further, the analysis showed early
signs of switches in co-receptor tropism, weeks before X4 viruses were detected by the
phenotypic assay used throughout the trial.
The prediction method presented in this work is currently lacking a critical feature,
which needs to be addressed in the future: The presence of a diverse quasispecies and
resulting mix of viruses present in the plasma during sequencing, often leads to unclear
base calls. A straightforward prediction on these ambiguous sequences is not possible.
Other methods have introduced ways of dealing with these sequences. Both PSSM and
geno2pheno are relying on a worst-case treatment, advising against treatment with CCR5
antagonists, should even a single ambiguous base call result in an X4 prediction. While
this is certainly a feasible approach, the performance with diﬀerent decision-making
processes should be elucidated.
4.2 Outlook
The impact of an accurate determination of co-receptor tropism on therapy outcome
has been highlighted on several occasions throughout this work. This emphasis will be-
come even stronger should co-receptor antagonists prove to be valuable ﬁrst-line drugs,
administered as part of standard HAART. Phenotypic methods have become more sen-
sitive. The enhanced sensitivity Troﬁle assay, for example, is able to detect minority
variants down to 0.3% of the total virus population. Questions concerning the predictive
power of genotypic methods have been addressed. Still, it is unclear whether predictions
made, based on the V3 loop region alone, are already optimal. For instance, discordance
between genotypic and phenotypic methods may results from bulk sequencing or fea-
tures in other tropism determining regions, such as the variable loop 2 (V2) of gp120
or even regions in gp41. These are currently not sequenced in clinical practice but have
been shown to improve accuracy when included into genotypic prediction [147]. Both,
phenotypic assays and genotypic prediction methods based on bulk sequences are cur-
rently unable to provide information about virus population dynamics or structures. By
combining next-generation sequencing with genotypic prediction methods, this feature
has been addressed in recent publications [151, 33, 3]. Under the same setting, very
satisfying concordance with phenotypic assay results has been described [145, 156], even
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oﬀering additional aspects that cannot currently be provided by cell-based assays [33].
Whether UDS is able to make an impact on routine clinical practice in diagnostics is
mostly a monetary question. Costs for technology, sequencing and infrastructure dealing
with the massive amounts of data have to drop further in order to make this technology
available to a broad spectrum of scientists and clinicians. The advantages for diagnostics
are at hand: regular, parallel sequencing of important regions of the major HIV drug
targets PR, RT, Env, IN, could reveal an advancing trend towards treatment failure.
This would, for the ﬁrst time, put clinicians in a position where a constant and eﬀective
suppression of viral load, even through phases of changes in therapy, seems possible.
However, until then, more knowledge has to be gathered. Future research has to include
determination of critical frequency thresholds of virus minorities, answering the ques-
tion at which frequency or population structure of X4 viruses co-receptor antagonists
should not be administered. For parallel drug resistance testing using next-generation
sequencing of viral quasispecies, it will be helpful to eﬀectively sequence only drug resis-
tance hotspots of the respective HIV proteins, while still maintaining a high prediction
accuracy. Recently, Steegen et al. have found good results in predicting drug resistances
using only a short fragment of the HIV-1 reverse transcriptase [143]. With the introduc-
tion of integrase inhibitors, similar studies will have to performed for the integrase. In
conclusion, it can be stated that the genotypic algorithms are not lacking accuracy, but
are rather limited by the type of sequencing applied.
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